CURRICULUM VITAE PERSONAL INFORMATION Name: David Robert Clemmons EDUCATION 1965-1966 Undergraduate, Vanderbilt University 1966

CURRICULUM VITAE

PERSONAL INFORMATION Name: David Robert Clemmons

EDUCATION 1965-1966 Undergraduate, Vanderbilt University 1966-1969 B.S., Davidson College 1970-1974 M.D. with honors, University of North Carolina at Chapel Hill

Postgraduate: 1974-1975 Intern in Medicine, Massachusetts General Hospital 1975-1976 Junior Assistant Resident, Massachusetts General Hospital 1976-1977 Senior Assistant Resident, Johns Hopkins Hospital 1977-1978 Clinical Fellowship in Endocrinology, Massachusetts General Hospital 1978-1980 Research Fellow in Cell Biology, Massachusetts General Hospital and the University of North Carolina at Chapel Hill

RESEARCH EXPERIENCE 1971-1972 USPHS Fellow in Pediatric Endocrinology 1978-1980 USPHS Fellow in Endocrinology

FACULTY APPOINTMENTS 1980-1984 Assistant Professor of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC 1984-1989 Associate Professor of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC 1989-present Professor of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC 1990-2006 Chief, Division of Endocrinology, University of North Carolina School of Medicine, Chapel Hill, NC 1995-present Sarah Graham Kenan Professor of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC 2006-2009 Director, Diabetes Center for Excellence, University of North Carolina School of Medicine, Chapel Hill, NC

TEACHING APPOINTMENTS 1974-1976 Clinical Fellow in Medicine, Harvard Medical School 1976-1977 Clinical Fellow in Medicine, Johns Hopkins Hospital 1977-1978 Clinical Fellow in Endocrinology, Harvard Medical School 1978-1980 Clinical and Research Fellow in Endocrinology, Harvard Medical School and the University of North Carolina at Chapel Hill

HONORS 1973 Deborah Cushing Leary Award 1974 Alpha Omega Alpha 1974 M.D. with honors

1 1974 James Bell Bullitt Award (Outstanding Senior Medical Student) 1978 National Research Service Award 1983 Jefferson-Pilot Fellow in Academic Medicine 1986 American Society of Clinical Investigation 1990 Chairman, Cell Biology and Physiology Study Section 1992 Chairman, Gordon Research Conference on Peptide Growth Factors 1995 Association of American Physicians 1999 Pharmacia-Upjohn Award for the best paper in the Journal of Clinical Endocrinology and Metabolism for 1998 2000 Citation by the Institute Scientific Information for being one of the 250 most cited scientists in the world in the fields of biology/biochemistry and clinical medicine between 1981-2000 2004 MERIT Award National Institutes of Health 2005 Aurbach Award, Endocrine Society

CERTIFICATION 1976 Diplomate, Internal Medicine (American Board of Internal Medicine) 1979 Diplomate, Endocrinology and Metabolism (American Board of Internal Medicine)

LICENSURE 1974-1979 Massachusetts 1974- North Carolina

PROFESSIONAL SOCIETIES Association of American Physicians American Society of Biological Chemistry American Society of Clinical Investigation Endocrine Society American Federation of Clinical Research Southern Society of Clinical Investigation American College of Physicians North Carolina Medical Society Association of General Clinical Research Center Directors American Diabetes Association Growth Hormone Research Society Association of Program Directors in Endocrinology Pituitary Society IGF Society

PROFESSIONAL SERVICE Consultancies: Monsanto Corporation, 11/10/82-1/1/02 Synergen, Inc., 12/12/86-12/31/90 Upstate Biotechnology, 1995-2004 Millipore, 2004-Present Genentech, Inc., 7/1/91-6/30/97 Nichols Institute Academic Associate, 5/1/90-12/11/99 Insmed Pharmaceuticals 4/1/00-3/31/2008

2 Celtrix Pharmaceuticals 1/1/92-4/15/01 Neurocrine, Inc 12/1/96-9/1/00 Academic Associate Quest Diagnostics 12/11/99-present Pharmacia 1/01/02- 3/31/03

AdHoc Consulting: Glaxo, Inc. Pfizer, Inc. Merck, Inc. Novartis, Inc. Chiron, Inc. Cephalon, Inc. Roche, Inc. Axys Pharmaceuticals Cor Therapeutics Bristol Myers Squibb Regeneron, Inc Ibsen, Inc Valero Pharmaceuticals Phyton Biotech Salix Pharmaceuticals Kowa Pharmaceuticals

Scientific Advisory Boards: Neurocrine, 9/1/96-6/30/2000 Sensus Corp., 1995-7/31/01 Celtrix, Inc., 11/1/90-4/11/2000 Genetech Center for Clinical Research 6/1/98-present Lilly Hypocs Advisory Board 7/1/00-present Thera Technologies 7/1/01-12/31/2009 Pfizer Worldwide Endocrinology Board 11/1/03-present Insmed Inc, 1/1/2000-5/1/2008

Editorial Boards: Associate Editor Cecils Textbook of Medicine 23rd and 24th Editions, 2006, 2010 Editor, Endocrine Reviews, 2011-present Editor, Endocrinology, 1993-2002 Editorial Board, Journal of Biological Chemistry, 1999-2004 Associate Editor, Journal of Cellular Physiology, 1989-present Member, Editorial Board, Endocrinology, 1990-1992 Member, Editorial Board, Journal of Cellular Biochemistry, 1990- 2004 Member, Editorial Board, Molecular Endocrinology 2006-

Reviewer ( > 3 yr.): Journal of Clinical Investigation Journal of Clinical Endocrinology Metabolism Endocrinology

Grant Review Panels: Member, Cell Biology and Physiology Study Section (CBY-2) 1986-1990 Ad Hoc reviewer, NIH (Endocrinology Study Section, NHLBI, Division of Research Resources, and NIA) 1990-Present

3 Meeting Member, Program Committee of the Endocrine Society, 1989-1992 Organization: Vice Chairman, Gordon Conference on Peptide Growth Factors, 1990 Chairman, Gordon Conference on Peptide Growth Factors, 1992 Annual Meeting Steering Committee Endocrine Society 2006-2009 Member Program Committee Growth Hormone Research Society Meeting, Arhus Denmark, October 1996. Member, Program Planning Committee IGF Society Meeting, Tokyo Japan, September 1998 Member, Program Committee Growth Hormone Research Society Meeting, San Francisco, Ca, September 2000. Member Program Committee Growth Hormone Research Society Meeting, Canes Australia, September 2002 Co Chair Planning Committee for HYPOCCS Meeting Central and peripheral mechanisms of pituitary disease, Miami Florida, April 2003. Chair, Serono Symposium on IGF-I and Growth New Orleans La, June, 2004. Member, Program Committee Growth Hormone Research Society, Boston, Ma, September 2004. Member, Program Committee Pituitary Society Meeting, San Diego, Ca, June 2005. Member, Program Planning Committee Growth Hormone and IGF Society Meeting, Kobe Japan, September 2006. Member, Program Committee 29th Annual KIGS/KIMS Meeting, Berlin, Germany, September 2007. CoChair, Program Committee 10th HYPOCCs Meeting, Hypothalamic- Pituitary Disease and Obesity, Vancouver, Ca, April 2008. Member, Program Committee Growth Hormone and IGF Society Meeting, Genoa Italy, September 2008. Co Chair, Planning Committee, Isben Foundation Symposium IGF’s Local Repair and Survival and Factors throughout the Lifespan. Paris, France, December 2008. CoChair, Program Committee Consensus Conference on GH and IGF-I assays. Kenswick, Virginia, October 2009. Member, Program Committee Growth Hormone and IGF-I Research Society, New York, NY, September 2010. Chair, Program Committee 33rd Annual KIMS/Kigs Meeting, Rome Italy, May 2011.

Officer: President, Pituitary Society 2003-2004 President Growth Hormone Research Society 2004-2006

RECENT GRANT SUPPORT Federal: 1981-2009 NIH 1-RO1 HL56850. Mechanisms by which IGF-I stimulates smooth muscle cells, PI. 1980-2014 NIH l RO1 AG0233l-26. Role of IGFBP-5 and integrins in controlling IGF- I actions, PI. 2004-2009 NIH PO1-AG24282. Changes in ROS systems and IGF-I roles in vascular aging, PI. 2006-2011 NIH-R41-HL084857-03. Development of a novel method of inhibiting atherosclerosis in diabetes, PI.

4 2011-2016 NIH R01-AR06114-01 Determination of the mechanism by which IGFBP- 2 stimulates bone remodeling Non Federal: 2008-2011 Juvenile Diabetes Research Foundation. Efficacy of an antiIAP antibody in blocking diabetic retinopathy.

COMMITTEES University: 1984-1987 Member, Faculty Council 1985-1987 Member, Faculty-Trustee Committee 1990-2000 Member, Patent Committee 1992-1999 Member, Advisory Committee to the Program on Molecular Biology 2008-present Member, Jefferson Pilot Awards, Committee

School of Medicine: 1979-present General Clinical Research Center Advisory Committee 198l-1987 Member, Critical Care Committee 1989 Biochemistry Chair Search Committee 1997 Pathology Chair Search Committee 1996 Biochemistry Chair Search Committee 1998-2002 Chairman, Gene Therapy Safety Subcommittee 2000-2004 Research Advisory Committee

National:

1997-2000 Council Member - Endocrine Society 1998-2001 Council of Directors, Association of Program Directors in Endocrinology and Metabolism

1999-present Council, Pituitary Society

International: 1995-present Member, Advisory Council Growth Hormone Research Society

ADMINISTRATIVE Associate Director, Clinical Research Unit, 1979-2005 Director, Clinical Endocrine Teaching Services, 1981-1989 Division Chief, Division of Endocrinology and Metabolism, 1990-2007 Associate Chair for Research, Department of Medicine, 1997-2007 Director, Diabetes Center of Excellence, 2006-present

TEACHING Lectures: Lectures to 2nd, 3rd, and 4th year medical students, 20 hours/year. Lectures to medical residents, 6 hours/year.

Lab: Teaching of medical students (summer only) and postdoctoral fellows on a daily basis.

5 Clinical: Fourth year students in Endocrine Clinic, l hour/week. Fourth year students on Endocrine Service, 2 hours/day (1 month/year).

CONTINUING EDUCATION Lecture in annual Internal Medicine Review Course, University of North Carolina at Chapel Hill. Area Health Education Centers (AHEC): 2-3 visits/year. Attending on Clinical Service: Endocrinology Consultation Service: 1 month/year.

AREAS OF RESEARCH INTEREST Basic: l. Role of V3 integrin and integrin activating protein in controlling smooth muscle cell responses to IGF-I. 2. Mechanisms by which hyperglycemia regulates insulin-like growth factor cellular actions. 3. Structure and function analysis of insulin-like growth factor binding proteins. 4. Role of IGF's in atherosclerosis and the response to injury.

Clinical: 1. Role of IGF-I and Growth Hormone in Controlling Insulin Sensitivity. 2. Metabolic responses to IGF-I administration in humans. 3. Use of IGF and IGFBP measurement to assess growth hormone status.

PUBLICATIONS Refereed:

1. Hintz RL, Clemmons DR, Underwood LE, Van Wyk JJ: Competitive binding of somatomedin to insulin receptors of adipocytes, chondrocytes and liver membranes. Proc. Natl. Acad. Sci. USA 69:235l-2353, 1972.

2. Clemmons DR, Hintz RL, Underwood LE, Van Wyk JJ: Common mechanisms of action of somatomedin and insulin on fat cells. Isr. J. Med. Sci. 10:l254-l263, 1974.

3. Clemmons DR, Van Wyk JJ, Ridgway ED, Kliman B, Kjellberg RN, Underwood LE: Evaluation of acromegaly by radioimmunoassay of somatomedin-C. N. Engl. J. Med. 301:1138-1142, 1979.

4. Clemmons DR, Underwood LE, Ridgway ED, Kliman B, Kjelberg RN, Van Wyk JJ: Estradiol treatment of acromegaly: Reduction of immunoreactive somatomedin-C and improvement in metabolic status. Am. J. Med. 69:57l-575, 1980.

5. Clemmons DR, Van Wyk JJ, Pledger WJ: Sequential addition of platelet factor and plasma to Balb/c 3T3 fibroblast cultures stimulates somatomedin-C binding early in the cell cycle. Proc. Natl. Acad. Sci. 77:6644-6648, 1980.

6 6. Clemmons DR, Underwood LE, Van Wyk JJ: Hormonal control of immunoreactive somatomedin production by cultured human fibroblasts. J. Clin. Invest. 67:l0-19, 198l.

7. Clemmons DR, Van Wyk JJ: Somatomedin-C and platelet-derived growth factor stimulate human fibroblast replication. J. Cell Physiol. 106:361-367, 198l.

8. Clemmons DR, Underwood LE, Ridgway EC, Kliman B, Van Wyk JJ: Hyperprolactinemia is associated with increased immunoreactive somatomedin-C in hypopituitarism. J. Clin. Endocrinol. Metab. 52:73l-735, 198l.

9. Clemmons DR, Klibanski A, Underwood LE, McArthur JW, Ridgway EC, Beitins IZ, Van Wyk JJ: Reduction in immunoreactive somatomedin-C during fasting in humans. J. Clin. Endocrinol. Metab. 53:l247-l250, 198l. l0. Ridgway EC, Klibanski A, Ladenson PW, Clemmons DR, Beitins IZ, McArthur JW, Martorana MA, Zervas NT: Pure alpha-secreting pituitary adenomas. N. Engl. J. Med. 304:l254-l259, 198l.

11. Wass JAH, Clemmons DR, Underwood LE, Barrow I, Besser G, Van Wyk JJ: Changes in circulating somatomedin-C levels in bromocriptine treated acromegaly. Clin. Endocrinol. l7:369-377, 1982.

12. Clemmons DR: Age-dependent production of a competence factor by human fibroblasts. J. Cell Physiol. 114:61-67, 1983. l3. Isley WL, Underwood LE, Clemmons DR: Dietary components that regulate serum somatomedin-C concentration in humans. J. Clin. Invest. 71:175-l82, 1983. l4. Clemmons DR, Underwood LE, Chatelain PG, Van Wyk JJ: Liberation of immunoreactive somatomedin-C from its binding proteins by proteolytic enzymes and heparin. J. Clin. Endocrinol. Metab. 56:384-389, 1983. l5. Clemmons DR, Isley WL, Brown MT: Dialyzable factor in human serum of platelet origin stimulates endothelial cell replication and growth. Proc. Natl. Acad. Sci. USA 80:1641-l645, 1983. l6. Clemmons DR, Shaw DS: Variables controlling somatomedin production by cultured human fibroblasts. J. Cell Physiol. 115:137-l42, 1983. l7. Clemmons DR: Multiple hormones stimulate the production of somatomedin by cultured human fibroblasts. J. Clin. Endocrinol. Metab. 58:850-856, 1984. l8. Isley WL, Underwood LE, Clemmons DR: Change in plasma somatomedin-C in response to ingestion of diets with variable protein and energy content. J. Parenteral Enteral Nutr. 8:407-411, 1984.

19. Clemmons DR: Interaction of circulating cell derived and plasma growth factors in stimulating cultured smooth muscle cell replication. J. Cell Physiol. 121:425-430, 1984.

20. Clemmons DR, Seek MM, Underwood LE: Supplemental essential amino acids augment the somatomedin-C/IGF-I response to refeeding after fasting. Metabolism 34:39l-395, 1985.

2l. Clemmons DR, Underwood LE, Dickerson RE, Brown RS, Hak LS, MacPhee RD, Heizer WD: Use of plasma somatomedin-C/insulin-like growth factor I measurements to monitor the response to nutritional repletion in malnourished patients. Am. J. Clin. Nutr. 41:191-198, 1985.

22. Clemmons DR: Variables controlling the production of a somatomedin-like peptide by cultured porcine smooth muscle cells. Circ. Res. 56:4l8-426, 1985.

23. Clemmons DR: Exposure to platelet derived growth factor modulates the porcine aortic smooth muscle cell response to somatomedin-C. Endocrinology 117:77-83, 1985.

24. Clemmons, DR, James PD and Elgin RG: Target cell actions of IGF-I on human fibroblast replication. J. Cell Biology 30:1412-1417, 1985.

25. Clemmons DR, Van Wyk JJ: Evidence for a functional role of endogenously produced somatomedin-like peptides in the regulation of DNA synthesis in cultured human fibroblasts and porcine smooth muscle cells. J. Clin. Invest. 75:19l4-19l8, 1985.

26. Clemmons DR, Elgin RG, Han VKM, Casella SJ, D'Ercole AJ, Van Wyk JJ: Cultured fibroblast monolayers secrete a protein that alters the cellular binding of somatomedin-C insulin-like growth factor I. J. Clin. Invest. 77:l548-l566, 1986.

27. Brown MT, Clemmons DR: Platelets contain a peptide inhibitor of endothelial cell replication and growth. Proc. Natl. Acad. Sci: 83:332l-3325, 1986.

28. Clemmons DR, Shaw DS: Purification and biologic properties of fibroblast somatomedin. J. Biol. Chem. 261:10293-l0299, 1986.

29. Brown MT, Busby WH and Clemmons DR: Structural determination of a low molecular weight mitogen for aortic endothelium. J. Biol. Chem. 261:13001-l3008, 1986.

30. Clemmons DR, Elgin RG: Somatomedin-C binding to cultured human fibroblasts is dependent upon donor age and culture density. J. Clin. Endo Metab. 63:996-1001, 1986.

31. Vender RL, Clemmons DR, Kwock L, Friedman M: Hypoxia induces pulmonary endothelium to release a smooth muscle cell mitogen. Amer. Rev. Resp. Dis. l35:622-627, 1987.

32. Smith AT, Clemmons DR, Ben Ezra VT, McMurry R, Underwood LE: Exercise modulates the response of somatomedin-C to dietary restriction. Metabolism 36:555-559, 1987.

33. Clemmons DR, Han VKM, Elgin RG, D'Ercole AJ: Alterations in the synthesis of a fibroblast surface associated 35K protein modulates the binding of somatomedin- C/insulin-like growth factor I. Mol. Endocrinol. l:339-347, 1987.

34. Elgin RG, Busby WH, Clemmons DR: An insulin-like growth factor (IGF) binding protein enhances the biologic response to IGF-I. Proc. Natl. Acad. Sci. 84:3254-3258, 1987.

8 35. Clemmons DR, Williams R, Snyder DK, Underwood LE: Treatment with growth hormone conserves lean body mass during dietary restriction in obese volunteers. J. Clin. Endo. Metab. 64:878-883, 1987.

36. Herman BA, Roe MW, Harris C, Wray B, Clemmons DR: Platelet derived growth factor induced alterations in vinculin distribution in porcine vascular smooth muscle cells. Cell Motility and Cytoskeleton 8:9l-95, 1987.

37. McCusker RH, Campion DA, Clemmons DR: The ontogeny and regulation of a 3l,000 molecular weight of insulin-like growth factor binding protein in fetal porcine plasma and sera. Endocrinology 122:2071-2079, 1988.

38. Dehoff MH, Elgin RG, Collier RJ, Clemmons DR: Both type I and II insulin like growth factor receptor binding increases during bovine lactation. Endocrinology l22:24l2-24l7, 1988.

39. Brown MT, Busby WH and Clemmons DR: Diadenosine tetraphosphate is a potent endothelial mitogen. American J. Physiol.Cell Physiol. 246:90l-9ll, 1988.

40. Snyder, DK, Clemmons DR, Underwood LE: Treatment of obese, diet restricted subjects with growth hormone for 11 weeks: Effects on anabolism lipolysis and body composition. J. Clin. Endo. Metab. 67:54-6l, 1988.

41. Busby WH, Klapper DG, Clemmons DR: Purification of a 3l,000 dalton somatomedin-C binding protein from human amniotic fluid: Isolation of two forms with different biologic actions. J. Biol. Chem. 263:l4203-l42l0, 1988.

42. Brewer ME, Stelter GL, Squires CH, Thompson RG, Busby WH, Clemmons DR: Cloning characterization and expression of an insulin like growth factor binding protein. Biochem. Biophys. Res. Comm. l52:l289-l297, 1988.

43. McCusker RH, Clemmons DR: Insulin-like growth factor binding protein secretion by muscle cells: Effect of cellular differentiation and proliferation. J. Cell Physiol. l37:505- 5l2, 1988.

44. Chiariotti L, Brown AL, Frunzio R, Clemmons DR, Rechler MM and Bruni CB: Structure of the rat insulin-like growth factor II transcriptional unit: heterogenous transcripts are generated from two promoters by use of multiple polyadenylation sites and differential ribonucleic acid splicing. Mol. Endocrinol. 2:lll5-ll26, 1988.

45. Busby WH, Snyder DK, Clemmons DR: Radioimmunoassay of a 3l,000 dalton IGF or binding protein: Control by nutritional variables. J. Clin. Endo. Metab. 67:l225-l230, 1988.

46. Clemmons DR, McCusker RH, Johnson MG, Busby WH: An antibody to an IGF binding protein inhibits the human fibroblast replication response to IGF-I. J. Cell Physiol. l38:4l- 49, 1988.

47. Clemmons DR, Dehoff M, Drop LS: Biosynthesis of 35K insulin like growth factor I binding protein by cultured human fibroblasts. Endocrinology l23:323-330, 1988.

9 48. Friedman M, Clemmons DR: Lung endothelium synthesis and release a connective tissue mitogen during hypoxia. Amer. J. Phys: Cell Physiol. 248:l24-l32, 1988.

49. Davenport ML, Svoboda ME, Korber KL, Van Wyk JJ, Clemmons DR, Underwood LE: Plasma concentrations of insulin-like growth factor II (IGF II) are not changed by short term fasting and refeeding. J. Clin. Endo. Metab. 67:l23l-l236, 1988.

50. Hill DJ, Clemmons DR, Wilson S, Han VKM, Strain AJ, Milner RGD: Immunologic distribution of one form of insulin-like growth factor (IGF) binding protein and IGF peptides in human fetal tissue. J. Mol. Endocrinol. 2:3l-38, 1989.

51. McCusker RH, Camacho-Hubner C, Clemmons DR: Identification of the types of insulin- like growth factor binding proteins that are secreted by muscle cells in vitro. J. Biol. Chem. 264:7795-7800, 1989.

52. Hill DJ, Camacho-Hubner C, Rashid D, Strain AJ, Clemmons DR: Insulin-like growth factor (IGF) binding protein release by human fetal fibroblasts: Dependency on cell density and IGF peptides. J. Endocrinol. l22:87-98, 1989.

53. Tollefson SE, Lajera R, McCusker RH, Clemmons DR, Rotwein P: Insulin-like growth factors in muscle development: Expression of IGF-I the IGF receptor and IGF binding protein during myoblast differentiation. J. Biol. Chem. 264:l38l0-l38l7, 1989.

54. McCusker RH, Campion DR, Jones WK, Clemmons DR: The insulin-like growth factor binding protein in porcine serum: Endocrine and nutritional regulation. Endocrinol. l25:50l-509, 1989.

55. Busby WH, Hossenlopp P, Binoux M, Clemmons DR: Purified forms of the amniotic fluid derived IGF binding protein contain multimeric forms that are biologically active. Endocrinol. l25:773-777, 1989.

56. Busby WH, Clemmons DR: Purification and structural characterization of an endothelial growth inhibitor. J. Biol. Chem. 264:l4l19-l4l26, 1989.

57. Snyder DK, Clemmons DR, Underwood LE: Diet composition modulates growth hormone responsiveness in humans. J. Clin. Endo. Metab. 69:777-784, 1989.

58. Clemmons DR, Thissen JP, Maes M, Ketelslegers JM, Underwood LE: IGF-I infusion into hypophysectomized or protein deprived rats induces specific IGF binding proteins in serum. Endocrinology 125:2967-2973, 1989.

59. Snyder DK, Underwood LE, Clemmons DR: Anabolic effects of growth hormone in obese diet restricted subjects are dose dependent. Amer. J. Clin. Nutr., 52:431-437, 1990.

60. Clemmons DR, Thrailkill KM, Handwerger S, Busby WH: Three distinct forms of insulin-like growth factor binding proteins are released by decidual cells in culture. Endocrinology 127:643-650,1990.

61. Bar RS, Boes M, Clemmons DR, Busby WH, Sandra A, Dake BL, Booth BA: Insulin differentially alters transcapillary movement of intravascular IGFBP-1, IGFBP-2 and endothelial cell IGF binding proteins in rat heart. Endocrinology 127:497-499, 1990.

10 62. Bar RS, Clemmons DR, Busby WH, Boes M, Booth BA, Dake BL, Sandra A: Transcapillary permeability and subendothelial distribution of endothelial and amniotic fluid (IGFBP-1) IGF-binding proteins in the rat heart. Endocrinology 127:1078-1086, 1990.

63. Thrailkill KM, Clemmons DR, Busby WH, Handwerger S: Differential regulation of IGF- binding protein (IGFBP) secretion from human decidual cells by IGF-I insulin and relaxin. J. Clin. Invest. 86:878-883, 1990.

64. McCusker RH, Camacho-Hubner C, Bayne ML, Cascieri MA, Clemmons DR: Insulin-like growth factor (IGF) binding to human fibroblast and glioblastoma cells: The modulating effect of cell released GF binding proteins (IGFBP's). J. Cell. Physiol. 144:244-251, 1990.

65. Clemmons DR, Cascieri MA, Camacho-Hubner C, McCusker RH, Gardner LW and Bayne MR: Distinct alterations of the IGF-I molecule that alter its affinity for IGF binding proteins result in changes in bioactivity. J. Biol. Chem. 265:12210-12216, 1990.

66. Davenport ML, Clemmons DR, Miles MW, Camacho-Hubner C, D'Ercole AJ, Underwood LE: Regulation of serum insulin-like growth factor I(IGF-I) and IGF binding proteins in rat pregnancy. Endocrinology 127:1278-1286, 1990.

67. Clemmons DR, Gardner LI: A plasma factor is required for IGFBP-1 to potentiate DNA synthesis. J. Cell. Physiol. 145:129-135, 1990.

68. Snyder DK, Clemmons DR: Insulin dependent regulation of insulin-like growth factor binding protein-1. J. Clin. Endocrinol. Metab., 71:1632-1636, 1990.

69. Clemmons DR, Camacho-Hubner CC, Carlton E, Osborne CK: Insulin-like growth factor binding protein secretion by breast carcinoma cell lines: Correlation with estrogen receptor status. Endocrinology, 127:2679-2686, 1990.

70. Fontana JA, Burrows-Mezu A, Clemmons DR, LeRoith D: Retinoid modulation of insulin-like growth factor binding proteins and inhibition of breast carcinoma proliferation. Endocrinology, 128:1115-1122, 1991.

71. Thissen JP, Underwood LE, Maiter D, Maes M, Clemmons DR, Ketelslegers JM: Failure of IGF-I infusion to promote growth in protein restricted rats despite normalization of serum IGF-I concentrations. Endocrinology, 128:885-890, 1991.

72. Kobayashi S, Clemmons DR, Venkatachalam MA: Co-localization of insulin-like growth factor binding protein with insulin-like growth factor I in rat kidney. Amer J Physiol, 261:F22-28, 1991.

73. Pape GS, Freidman M, Underwood LE, Clemmons DR: Effect of growth hormone on weight gain and pulmonary function in patients with chronic obstructive lung disease. Chest, 99:1495-1500, 1991.

74. Jones JI, D'Ercole AJ, Clemmons DR: Phosphorylation of insulin-like growth factor binding protein in cell culture and in vivo: effects on affinity for IGF-I. Proc Natl Acad Sci USA, 88:7481-7485, 1991.

11 75. Clemmons DR, Snyder DK, Busby WH: Variables controlling the secretion of insulin-like growth factor binding protein-2 in normal human subjects, J. Clin. Endocrinol. Metab., 73:727-733, 1991.

76. McGrath MF, Collier RJ, Clemmons DR, Busby WH, Sweeny CA, Krivi GC: The direct effect of insulin-like growth factors (IGFs) on normal bovine mammary cell proliferation and production of IGF binding proteins: an in vitro study. Endocrinology, 129:671-678, 1991.

77. Camacho-Hubner C, Clemmons DR, D'Ercole AJ: Regulation of insulin-like growth factor (IGF) binding proteins in transgenic mice with altered expression of growth hormone and IGF-I. Endocrinology, 129:1201-1206, 1991.

78. McCusker RH, Busby WH, Dehoff M, Camacho-Hubner C, Clemmons DR: Insulin-like growth factor binding to cell monolayers is directly modulated by the addition of insulin- like growth factor binding proteins. Endocrinology, 129:939-951, 1991.

79. Cohick WS, Clemmons DR: Regulation of insulin-like growth factor binding protein synthesis and secretion in a bovine epithelial cell line. Endocrinology, 129:1347-1354, 1991.

80. Camacho-Hubner C, McCusker RH, Clemmons DR: Secretion and biologic actions of the insulin-like growth factor binding proteins in two human tumor derived cell lines in vitro. J. Cell. Physiol., 148:281-289, 1991.

81. Vicini JL, Buonomo FC, Veenhuizein JJ, Miller MA, Clemmons DR, Collier RJ: Effects of nutritional balance and stress of lactation in dairy cows on insulin, insulin-like growth factors I and II and insulin-like growth factor binding protein 2 responses to somatotropin administration. J. Nutr., 121:1656-1664, 1991.

82. McCusker RH, Cohick WS, Busby WH, Clemmons DR: Evaluation of the developmental and nutritional changes in porcine insulin-like growth factor binding protein-1 and 2 serum levels by immunoassay. Endocrinology, 129:2631-2638, 1991.

83. Bourner MJ, Busby WH, Seigel NR, Krivi GG, McCusker RH, Clemmons DR: Cloning and sequence determination of bovine IGFBP-2: Comparison of its structural and functional properties with IGFBP-1. J. Cell Biochem., 48:215-226, 1992.

84. Clemmons DR, Smith-Banks A, Underwood LE: Reversal of diet induced catabolism by infusion of recombinant insulin-like growth factor-I (IGF-I) in humans. J. Clin. Endocrinol. Metab., 75:234-238, 1992.

85. Cohick WS, McGuire MA, Clemmons DR, Bauman DE: Regulation of IGF binding proteins in serum and lymph of lactating cows by somatotropin. Endocrinology, 130:1508-1514, 1992.

86. Hill DJ, Clemmons DR: Similar distribution of insulin-like growth factor binding proteins 1, 2 and 3 in human fetal tissues. Growth Factors, 6:315-326, 1992.

87. Davenport ML, Pucilowska J, Clemmons DR, Lundblad R, Spencer JA, Underwood LE: Tissue specific expression of IGFBP-3 protease activity during rat pregnancy. Endocrinology, 130:2505-2512, 1992.

88. Camacho-Hubner C, Busby WH, McCusker RH, Wright G, Clemmons DR: Identification of insulin-like growth factor binding proteins produced by human fibroblasts and the mechanisms that regulate their secretion. J. Biol. Chem., 267:11949-11956, 1992.

89. Sheikh MS, Shao ZM, Clemmons DR, LeRoith D, Roberts CT, Fontana JA: Identification of the insulin-like growth factor binding proteins-5 and 6 in human breast cancer cells. Biochem Biophys Res Commun, 183:1003-1010, 1992.

90. Clemmons DR, Dehoff ML, Busby WH, Bayne ML, Cascieri MA: Competition for binding to IGFBP-2, 3, 4 and 5 by insulin-like growth factors and IGF analogs. Endocrinology, 130:890-895, 1992.

91. Davenport ML, Isley WL, Pucilowska J, Pemberton B, Lyman B, Underwood LE, Clemmons DR: Insulin-like growth factor binding protein-3 proteolysis is induced following elective surgery. J. Clin. Endocrinol. Metab., 75:590-595, 1992.

92. Young SCJ, Underwood LE, Celniker AC, Clemmons DR: Effects of recombinant insulin- like growth factor I (IGF-I) and growth hormone (GH) on serum IGF binding proteins in calorically restricted adults. J. Clin. Endocrinol. Metab., 75:603-608, 1992.

93. Young SCJ, Miles MV, Clemmons DR, Determination of the pharmacokinetic profiles of IGFBP-1 and IGFPB-2 in rats. Endocrinology, 131: 1867-1873, 1992.

94. Adamo ML, Shao ZM, Lanau F, Chen JC, Clemmons DR, Roberts CT, LeRoith D, Fontana JA, Insulin like growth factor I (IGF-I) and retinoic acid modulation of IGF binding proteins (IGFBP's). IGFBP-2, 3 and 4 gene expression and protein secretion in a breast cancer cell line. Endocrinology, 131: 1858-1866, 1992.

95. Sheikh MS, Shao ZM, Chen JC Clemmons DR, Roberts CT, LeRoith D, Fontana JA: Insulin like growth factor expression is differentially regulated at a post transcriptional level in retinoic acid sensitive and resistant MCF-7 human breast carcinoma cells. Biochem Bioph Res Comm, 188:1122-1130, 1992.

96. Moser DR, Loew WL, Dake BL, Booth BA, Boes M, Clemmons DR, Bar RS: Endothelial cells produce IGFBP-2 IGFBP-3 and IGFBP-4. Mol. Endocrinol., 6: 1805-1814, 1992.

97. Schoen TJ, Beebe DC, Clemmons DR, Chader GJ, Waldbillig RJ: Local synthesis and developmental regulation of avian vitreal insulin like growth factor binding proteins: A model for independent regulation in extravascular and vascular compartments. Endocrinology, 131: 2846-2854, 1992.

98. Hill DJ, Clemmons DR, Bassett N, Challis JRG: Immunohistochemical localization of insulin like growth factors (IGF's) and IGF binding proteins 1-2 and 3 in human placenta and fetal membranes. Placenta, 14:1-12, 1993.

99. Jones JI, Busby WH, Wright G, Smith CE, Kimack NM, Clemmons DR: Identification of the sites of phosphorylation in insulin-like growth factor binding protein-1: Regulation of its affinity by phosphorylation of serine 101. J. Biol. Chem., 268: 1125-1131, 1993.

13 100. Kupfer SR, Underwood LE, Baxter RC, Clemmons DR: Enhancement of the anabolic effects of growth hormone and insulin-like growth factor-I by the use of both agents simultaneously. J. Clin. Invest., 91: 391-396, 1993.

101. Backeljaw PF, Clemmons DR, D'Ercole AJ: Synthesis and regulation of insulin like growth factor binding protein-5 (IGFBP-5) in FRTL-5 cells. Endocrinology, 132:1677- 1681, 1993.

102. Cohen P, Peehl DM, Staney TA, Wilson KF, Clemmons DR, Rosenfeld RE: Elevated levels of insulin like growth factor binding protein-2 in prostate cancer patients. J. Clin. Endocrinol. Metab, 76: 1031-1035, 1993.

103. Jones JI, Busby WH, Gockerman A, Camacho-Hubner C, Clemmons DR: Extracellular matrix contains insulin-like growth factor binding protein-5: Potentiation of the effects of IGF-I. J. Cell Biol., 121: 679-687, 1993.

104. Sheikh MS, Shao ZM, Hussain A, Clemmons DR, Chen JC, Roberts CT, LeRoith D, Fontana JA: Regulation of insulin like growth factor binding protein 1, 2, 3, 4, 5 and 6. Synthesis, secretion and gene expression in estrogen receptor negative human breast carcinoma cells. J. Cell Physiol, 155:556-567, 1993.

105. Cohick WS, Gockerman A, Clemmons DR: Vascular smooth muscle cells synthesize two forms of insulin like growth factor binding proteins (IGFBP) which are regulated differently by the IGF's. J. Cell Physiol, 157:52-60, 1993.

106. James PL, Jones SB, Busby WH, Clemmons DR, Rotwein P: IGF binding protein-5 is expressed in myoblast differentiation and is highly conserved. J. Biol Chem, 268:22305- 22312, 1993.

107. Smith WJ, Nam TK, Underwood LR, Celnicker A, Clemmons DR: Use of insulin like growth factor binding protein-2 (IGFBP-2), IGFBP-3 and IGF-I for assessing growth hormone status in short children. J. Clin Endo Metab, 77:1294-1299, 1993.

108. Pucilowska JB, Davenport ML, Kabir I, Clemmons DR, Thissen JP, Butler T., Underwood LR: The effect of dietary protein supplementation IGF's and IGFBP's in children with shigellosis. J. Clin Endo Metab, 77:1516-1521, 1993.

109. Jones JI, Gockerman A, Busby WH Jr., Wright G, Clemmons DR: Insulin like growth factor binding protein-1 stimulates cell migration and binds to the 5B1 integrin via its arg-gly-asp sequence. Proc. Natl Acad Sci, 90:10553-10557, 1993.

110. Hogg J, Han VKM, Clemmons DR, Hill DJ: Interactions of nutrients, insulin-like growth factors (IGF's) and IGF binding proteins in the regulation of DNA synthesis by isolated fetal islets of langenhans. J. Endocrinology, 138:401-412, 1993.

111. Jyung R, Mustoe T, Busby WH, Clemmons DR: Increased wound breaking strength induced by insulin-like growth factor-1 in combination with IGF binding protein-1. Surgery, 115:223-239, 1994.

112. Young SCJ, Clemmons DR: Changes in insulin-like growth factor (IGF)-binding proteins after IGF-I injections in noninsulin-dependent diabetics. J. Clin Endo Metab, 78:609-614, 1994.

113 Stanko RL, Cohick WS, Armstrong DW, Shaw RW, Harvey RW, Clemmons DR, Whitacre MD: Effect of somatotropin and (or) pregnant mare serum gonadotropin on serum and follicular IGF-I and IGF binding proteins in cattle. Biology of Reproduction, 50:290-300, 1994.

114. McCusker RH, Clemmons DR: Effects of cytokines on insulin like growth factor binding protein secretion by muscle cells in vitro. Endocrinology, 134:2095-2102, 1994.

115. Kou K, James PL, Clemmons DR, Copeland NG, Gilbert OJ, Jenkins NA, Rotwein P: Identification of two clusters of mouse insulin-like growth factor binding protein genes on chromosomes 1 and 11. Genomics, 21:651-653, 1994.

116. Cohick WS, Clemmons DR: Enhanced expression of dihydrofolate reductase by bovine kidney epithelial cells results in altered cell morphology, IGF-I responsiveness, and IGF binding protein-3 expression. J. Cell Physiol, 161:178-186, 1994.

117. Arai T, Parker AJ, Busby WH, Clemmons DR: Heparin, heparan sulfate and dermatan sulfate regulate formation of the insulin like growth factor-I and IGF binding protein complexes. J. Biol Chem, 269:20388-20393, 1994.

118. Nam TJ, Busby WH Jr, Clemmons DR: Human fibroblasts secrete a serine protease that cleaves insulin like growth factor binding protein-5. Endocrinology, 135:1385-1391, 1994.

119. Arai T, Arai T, Busby WH Jr, Clemmons DR: Glycosaminoglycans inhibit degradation of insulin-like growth factor binding protein-5. Endocrinology, 135:2358-2363, 1994.

120. D'Ercole AJ, Dai Z, Xing Y, Boney C, Wilkie MB, Lauder JM, Han VKM, Clemmons DR: Brain growth retardation due to the expression of human insulin-like growth factor binding protein-1 (IGFBP-1) in transgenic mice: an in vivo model for the analysis of IGF function in the brain. Develop Brain Research, 82:213-222, 1994.

121. Dai Z, Xing Y, Boney CM, Clemmons DR, D'Ercole AJ: Human insulin-like growth factor binding protein-1 (hIGFBP-1) transgenic mice: characterization and insights into the regulation of IGFBP-1 expression. Endocrinology, 135:1316-1327, 1994.

122. D’Ercole AJ, Dai Z, Xing Y, Boney C, Wilkie MB, Lauder JM, Han VK, Clemmons DR. Brain growth retardation due to the expression of human insulin-like growth factor binding protein-1 in transgenic mice: an in vivo model for the analysis of IGF function in the brain. Brain Res Dev Brain Res 82:231-22, 1994.

123. Snyder DK, Underwood LE, Clemmons DR: Persistent lipolytic effect of exogenous growth hormone during caloric restriction. Amer J Med, 98:129-134, 1995.

124. Smith WJ, Underwood LE, Clemmons DR: Effects of caloric or protein restriction on insulin like growth factor I (IGF-I) and IGF binding proteins (IGFBPs) in children and adults. J. Clin Endo Metab, 80:443-449, 1995.

125. Jones JI, Clemmons DR: Insulin-like growth factors and their binding proteins: biologic actions. Endocrine Rev, 16:3-34, 1995.

15 126. Grinspoon S, Clemmons DR, Swearingen B, Klibanski A: Diagnostic use of IGFBP-3 levels in acromegaly. J. Clin Endo Metab, 80:927-932, 1995.

127. Koybayashi S, Venkatachalem MA, Clemmons DR, Roy AK, Stein JH: Workload induced by furosemide increases IGF-I and IGFBP-1 in rat distal nephrom. Kidney Inter, 34:818- 828, 1995.

128. Gockerman A, Clemmons DR: Porcine aortic smooth muscle cells secrete a serine protease for insulin like growth factor binding protein-2. Circ Res, 76:514-521, 1995.

129. Cohick WS, Gockerman A, Clemmons DR: Regulation of insulin like growth factor (IGF) binding protein-2 synthesis and degradation by platelet derived growth factor and IGF's is enhanced by serum deprivation in vascular growth muscle cells. J. Cell Physiol, 164:187-196, 1995.

130. Parker A, Gockerman A, Busby WH, Clemmons DR: Properties of an insulin like growth factor binding protein 4 protease that is secreted by smooth muscle cells. Endocrinology, 136:2470-2476, 1995.

131. Chernausek SD, Smith CE, Diffin KL, Busby WH, Wright G, Clemmons DR: Proteolytic cleavage site of insulin like growth factor binding protein-4 (IGFBP-4). J. Biol Chem 270:11377-11382, 1995.

132. Gockerman A, Jones JI, Prevette T, Clemmons DR: Insulin like growth factor binding protein-2 inhibits smooth muscle cell migration response to IGF-I. Endocrinology, 136:4168-4173, 1995.

133. Duan C, Clemmons DR: Transcription factor AP-2 regulates human insulin like growth factor binding protein-5 gene expression. J. Biol. Chem, 270:24844-24851, 1995.

134. Veldhuis JD, Liem AY, Weltman A, South S, Weltman J, Clemmons DR, Abbott R, Mulligan T, Johnson ML, Pincus S, Straume M, Iranmanesh A. Differential impact of age, sex steroid hormones, and obesity on basal vs pulsatile growth hormone secretion in men as expressed in an ultrasensitive chemiluminescence assay. J Clin End Metab, 8:3209- 3222, 1995.

135. Moses AC, Young SCJ, Morrow LA, O'Brien MA, Clemmons DR: Recombinant human insulin like growth factor-I increases insulin sensitivity and improves glycemic control in type II diabetes mellitus. Diabetes, 45:91-100,1996.

136. Baum HA, Biller BK, Katznelson L, Oppenheim DS, Clemmons DR, Caminstranok B, Schoenfeld DA, Best SA, Klibanski A: Assessment of growth hormone (GH) secretion in men with adult onset GH deficiency compared with normal men. J. Clin. Endo. Metab, 81:84-92, 1996.

137. Jones JI, Prevette T, Gockerman A, Clemmons DR: Ligand occupancy of the V3 integrin is necessary for smooth muscle cells to migrate in response to IGF-I. Proc Natl Acad Sci, 93:2462-2467, 1996.

138. Ankrapp DP, Jones JI, Clemmons DR: Characterization of insulin like growth factor binding protein-1 kinases from human hepatoma cells. J Cell Biochem 60:387-399, 1996.

16 139. Arai T, Clarke S, Parker A, Busby WH, Clemmons DR: Effect of substitution of specific amino acids in insulin like growth factor binding protein-5 on heparin binding and its change in affinity for IGF-I in response to heparin. J. Biol. Chem., 271:6099-6106, 1996.

140. Duan C, Hawes S, Prevette T, Clemmons DR: Insulin like growth factor-I (IGF-I) stimulates IGF binding protein-5 synthesis through transcriptional activation of the gene in aortic smooth muscle cells. J. Biol. Chem, 271:4280-4288, 1996.

141. Parker A, Busby WH, Clemmons DR: Identification of the extracellular matrix binding site for insulin like growth factor binding protein-5. J. Biol Chem, 271:13523-13529, 1996.

142. Arai T, Busby WH, Clemmons DR: Binding of insulin-like growth factor I or II to insulin- like growth factor binding protein-2 (IGFBP-2) enables it to bind to heparin and extracellular matrix. Endocrinology, 137:4571-4575, 1996.

143. Nam TJ, Busby WH, Clemmons DR: Characterization and determination of the relative abundance of two types of IGFBP-5 proteases that are secreted by human fibroblasts. Endocrinology, 137:5530-5536, 1996.

144. Galiano RD, Zhao LL, Clemmons DR, Roth SI, Xuanhan DS, Mustoe TA: Interaction between insulin-like growth factor family and integrin receptor family in tissue repair processes: Evidence in a rabbit ear dermal ulcer model. J Clin Invest, 98:2462-2468, 1996.

145. Nam TJ, Busby WH, Clemmons DR: Insulin-like growth factor binding protein-5 binds to plasminogen activator inhibitor-I. Endocrinology 138:2972-2998, 1997.

146. McCusker RH and Clemmons DR: Use of lanthanum to accurately quantify insulin-like growth factor binding to proteins on cell systems. J Cell Biochem 66:256-267, 1997.

147. Geffner LJ, Benoit LA, Clemmons DR, Copeland KC: The secretion of insulin-like growth factor I, prolactin and insulin-like growth factor binding protein-1 by decidua as predictors of human fetal growth. Growth Regulation 7:1-6, 1997.

148. Imai Y, Busby WH, Smith CE, Clarke JB, Horvitz GD, Rees C, Clemmons DR: Protease resistant form of insulin-like growth factor binding protein-5 is an inhibitor of insulin- like growth factor-I actions in porcine smooth muscle cells in culture. J Clin Invest 100:2596-2606, 1997.

149. Smith WJ, Underwood LE, Keyes L, Clemmons DR: Use of insulin-like growth factor I (IGF-I) and insulin-like growth factor binding protein measurements to monitor feeding of premature infants. J Clin Endo Metab 82:3982-3988, 1997.

150. Hijo H, Duan C, Clemmons DR, Herman B: Retinoic acid inhibits growth in HPV negative cervical carcinoma cells by induction of insulin-like growth factor binding protein-5 (IGFBP-5) secretion. Biochem Biophys Res Comm 239:706-709, 1997.

151. Wallen LD, Myint W, Nygard K, Shimasaki S, Clemmons DR, Han VKM: Cellular distribution of insulin-like growth factor binding protein mRNAs and peptides during rat lung development. J. Endocrinology 155:317-327, 1997.

17 152. McCusker RH, Clemmons DR: A role for cyclic adenosine monophosphate (cAMP) in modulating insulin-like growth factor binding protein secretion. J Cell Physiol 174:293- 300, 1998.

153. Murphy MG, Plunkett LM, Polvino WM, He W, Wittreich J, Gertz BJ, Clemmons DR: MK677: An orally active growth hormone (GH) secretagogue reverses diet-induced catabolism. J Clin Endo Metab 83:320-326, 1998.

154. Jacot T, Clemmons DR: The effect of glucose on insulin-like growth factor binding protein-4 proteolysis. Endocrinology 139:44-50, 1998

155. Clemmons DR: Role of insulin-like growth factor binding proteins in controlling IGF actions. Molecular and Cellular Endocrinology 140:19-24, 1998.

156. Zheng B, Clarke JB, Busby WH, Duan C, Clemmons DR: Insulin-like growth factor binding protein-5 (IGFBP-5) is cleaved by physiologic concentrations of thrombin. Endocrinology, 139:1708-1714, 1998.

157. Zheng B, Duan C, Clemmons DR: The effect of extracellular matrix proteins on porcine smooth muscle cell insulin-like growth factor binding protein-5 synthesized response to IGF-I. J. Biol Chem, 273:8994-9000 1998.

158. Duan C, Clemmons, DR: Differential expression and biological effects of insulin-like growth factor (IGF) binding protein-4 and -5 in vascular smooth muscle cells. J. Biol. Chem. 273(27):16836-16842, 1998.

159. Parker A, Rees C, Clarke JB, Busby WH, Clemmons DR: Binding of insulin-like growth factor binding protein-5 to smooth muscle cell extracellular matrix is a major determinant of the cellular response to IGF-I. Molecular Biology of the Cell 9:2383-2392, 1998.

160. Zheng B, Clemmons DR: 1998 Blocking ligand occupancy of the V3 integrin inhibits IGF-I signaling in vascular smooth muscle cells. Proc. Natl. Acad. Sci. USA, 95:11217- 11222, 1998.

161. Rees C, Clemmons DR: Inhibition of IGFBP-5 binding to extracellular matrix and IGF-I stimulated DNA synthesis by a peptide fragment of IGFBP-5. J Cellular Biochem 71:375- 381, 1998.

162. Rees C, Clemmons DR, Horvitz GD, Clarke JB, Busby WH: A protease-resistant form of insulin-like growth factor binding protein-4 (IGFBP-4) inhibits IGF-I actions. Endocrinology, 139:4182-4188, 1998.

163. Iranmanesh A, South S, Liem AY, Clemmons DR, Weltman A, Veldhuis JD: Unequal impact of age, percentage body fat, and serum testosterone concentrations on the somatotropic, IGF-I and IGF binding protein responses to a 3 day intravenous growth hormone releasing hormone pulsatile infusion in men. Eur J Endocrinol 139:59-71, 1998.

164. Imai Y, Clemmons DR: Roles of phosphatidyl inositol 3-kinase and mitogen-activated protein kinase pathways in stimulation of vascular smooth muscle cell migration by insulin-like growth factor-I. Endocrinology 140:4228-4235, 1999.

18 165. Clemmons DR, Horvitz G, Engleman W, Nichols T, Moralez A, Nickols A: Synthetic V3 antagonists inhibit IGF-I stimulated smooth muscle cell migration and replication. Endocrinology, 140:4616-4621, 1999.

166. Yano K, Bauchat JR, Liinalta MB, Clemmons DR, Duan C: Down regulation of protein kinase-C inhibits IGF-I-induced vascular smooth muscle cell proliferation, migration, and gene expression. Endocrinology 140:4622-4632, 1999.

167. Nichols TC, Dulaney T, Zheng B, Bellinger DA, Nickols A, Engleman W, Clemmons DR: Reduction in atherosclerotic lesion size in pigs by V3 inhibitors is associated with inhibition of insulin-like growth factor-I mediated signaling. Circ Res 85:1040-1045, 1999.

168. Badinga L, Song S, Simmen RC, Clarke JB, Clemmons DR, Simmen FA: Complex inhibition of uterine endometrial epithelial cell growth by insulin-like growth factor-II and IGF binding protein-2. J Mol Endocrinol 23:277-285, 1999.

169. Nam TJ, Busby WH, Clemmons DR: Interaction between thrombospondin or osteopontin and insulin-like growth factor binding protein-5 leads to alteration in IGF-I action. Endocrinology, 85:1627-1633, 2000.

170. Clemmons DR, Moses AC, McKay MJ, Sommer A, Rosen DM, Ruckle J: The combination of insulin-like growth factor-I and insulin-like growth factor binding protein-3 reduces insulin requirements in type 1 diabetes: evidence for in vivo biologic activity. J Clin Endocrinol, 85:1518-1524, 2000.

171. Yoshizawa A, Clemmons DR: Testosterone and insulin-like growth factor-I (IGF-I) interact in controlling IGF binding protein production in androgen responsive foreskin fibroblasts. J Clin Endocrinol, 85:1627-1633, 2000.

172. Akinci A, Copeland KC, Garmong A, Clemmons DR: Insulin-like growth factor binding proteins (IGFBPs 1, 2, and 3) in serum and urine and IGFBP-2 protease activity in patients with IDDM. Metabolism, 49:626-633, 2000.

173. Trainer PJ, Dreskee WM, Katznelson L, Freda PU, Herman-Bonnert U, Vander Lely AJ, Dinarok E, Stewart PM, Fried KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barker AL, Sheppard MC, Malasonedo M, Rose DR, Clemmons DR: Treatment of acromegaly with the growth hormone receptor antagonist Pegvisomant. NEJM, 342:1171-1177, 2000.

174. Imai Y, Moralez A, Andag U, Clarke JB, Busby WH, Clemmons DR: Substitutions for hydrophobic amino acids in the N terminal domain of IGFBP-3 and -5 markedly reduce IGF-I binding and alter their biologic actions. J Biol Chem, 275(24): 18188-94, 2000

175. Coschigano KT, Clemmons DR, Beolusch LL, Copchick JJ: Assessment of growth parameters and lifespan of GHR/BP gene-disrupted mice. Endocrinology 141:2608-2613, 2000.

176. Busby WH, Nam TJ, Moralez A, Smith C, Jennings M, Clemmons DR: The complement component C1s is the protease that accounts for cleavage of insulin-like growth factor binding protein-5 in fibroblast medium. J Biol Chem, 275:37638-37644, 2000.

177. Sakai K, Murphy L, D’Ercole AJ, Clemmons DR: Physiologic differences in insulin-like

19 growth factor binding protein-1 (IGFBP-1) phosphorylation in IGFBP-1 transgenic mice. Diabetes, 50:32-38, 2001.

178. Maile LA, Clemmons DR: Structural analysis of the role of 3 subunit of the V3 integrin in IGF-I signaling. J Cell Sci, 114:1417-1425, 2001.

179. Sakai K, Busby WH, Clark, JB, Clemmons DR: Tissue transglutaminase facilitates the polymerization of insulin-like growth factor binding protein-1 (IGFBP-1) leading to loss of its ability to inhibit insulin-like growth factor-I (IGF-I) stimulated protein synthesis. J. Biol Chem, 276:8740-8745, 2001.

180. Firth SM, Clemmons DR, Baxter RC: Mutagenesis of specific basic amino acid residues in the carboxyl regions of insulin-like growth factor binding protein-5 affects acid labile subunit binding. Endocrinol, 142:2146-2151, 2001.

181. Price WA, Lee E, Maynor A, Stiles AD, Clemmons DR: The relationship of serum IGF-I, IGFBP-2 and IGFBP-3 to nutritional intake is altered in ill premature infants. J. Ped Gastroenterology and Nutrition, 32:341-348, 2001.

182. Clemmons DR: Use of mutagenesis to probe insulin-like growth factor binding protein actions. Endocrine Reviews, 22:800-817, 2001.

183. Van der Lely AJ, Hutson K, Trainer P, Besser M, Barton AZ, Katznelson L, Klibanski A, Hermon-Bonet V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend K, Clemmons DR: Long term treatment of acromegaly with Pegvisomant, a growth hormone receptor antagonist. Lancet, 358:1754-1759, 2001.

184. Nam TJ, Moralez A, Clemmons DR: Vitronectin binding to insulin-like growth factor binding protein alters IGFBP-5 modulation of IGF-I actions. Endocrinology, 143:30-37, 2002.

185. Maile LA, Imai Y, Clarke JB, Clemmons DR: Insulin-like growth factor-I increases V3 affinity by increasing the amount of integrin associated protein that is associated with non RAFT domains of the cellular membrane. J. Biol. Chem, 277:1800-1805, 2002.

186. Lewis MI, Horvitz GD, Clemmons DR, Fournier M: Role of IGF-I and IGF binding proteins within diaphragm muscle in modulating the effects of nandrolone. Am J Physiol Endrocrinol Metab 282:E483-490, 2002

187. Hartman ML, Crowe BJ, Biller BM, Ho KY, Clemmons DR, Chipman JJ: Which patients do not require a growth hormone stimulation test for the diagnosis of adult GH deficiency? J. Clin. Endo Metab, 87:477-485, 2002.

188. Clemmons DR, Busby WH, Garmong A, Schultz DR, Howell DS, Carr R: Inhibition of IGFBP-5 proteolysis in articular cartilage and joint fluid results in enhanced concentrations of IGF-I and improved osteoarthritis. Arthritis and Rheumatism, 46: 694- 703, 2002.

189. Maile LA, Clarke JB, Clemmons DR: Regulation of insulin-like growth factor-I receptor dephosphorylation by SHPS-1 and SHP-2 tyrosine phosphatase. J Biol Chem, 277:8955- 8960, 2002.

20 190. Sakai K, Loman H, Clemmons DR: Increases in free unbound insulin-like growth factor- I enhances insulin responsiveness in human hepatoma G2 cells in culture. J. Biol. Chem. 277:13620-13627, 2002.

191. Perks CM, McCaig C, Clarke JB, Clemmons DR, Holly JM: Effects of a non-IGF binding mutant of IGFBP-5 on cell death in human breast cancer cell lines. Biochem. Biophys. Res. Comm. 294:995-1000, 2002.

192. Perks CM, McCaig C, Clarke JB, Clemmons DR, Holly J. A non-IGF binding mutant of IGFBP-3 modulates cell function in breast epithelial cells. Biochem. Biophys. Res. Comm. 294:988-994, 2002.

193. Maile LA, Clemmons DR. The αVβ3 integrin regulates IGF-I receptor phosphorylation by altering the rate of recruitment of the SHP-2 phosphatase to the activated IGF-I receptor. Endocrinology 143: 4259-4264, 2002.

194. O’Connell T, Clemmons DR. IGF-I/IGFBP-3 combination improves insulin resistance by GH dependent and independent mechanisms. J. Clin. Endo Metab, 87:4356-4360, 2002.

195. Rose DR, Clemmons DR. Growth Hormone receptor antagonist improves insulin sensitivity resistance in acromegaly. Growth Hormone and IGF Res, 12:418-242, 2002.

196. Grinspoon S, Thomas L, Miller K, Bodio K, Mulcahey M, Herzog D, Clemmons DR, Klibanski A: Effects of rhIGF-I and estrogen administration on IGF-I, IGFBP-2 and IGFBP-3 in anorexia nervosa: A randomized controlled study. J Clin Endo Metab 88:1142-1149, 2003

197. Sakai K, Clemmons DR. Glucosamine induces resistant to insulin-like growth factor (IGF- I) and insulin in Hep G-2 cell cultures:Biological significance of IGF-I/insulin hybrid receptors, Endocrinology 144: 2388-2395, 2003

198. Moralez A, Busby WH Jr, Clemmons DR. Control of insulin-like growth factor binding protein-5 protein synthesis and secretion by human fibroblasts and porcine aortic smooth muscle cells. Endocrinology 144: 2489-2495, 2003

199. Ling Y, Maile LA, Clemmons DR. Tyrosine phosphorylation of the 3 subunit of the V3 integrin is required for the membrane association of tyrosine phosphatase SHP-2 and its subsequent transfer to insulin-like growth factor-I receptor . Mol Endocrinol, 17:1824-1833, 2003

200. Maile LA, Clarke JB, Clemmons DR. The association between integrin associated protein and SHPS-1 regulates IGF-I receptor signaling in vascular smooth muscle cells. Mol Biol Cell, 14:3519-28, 2003

201. Hsieh T, Gordon RE, Clemmons DR, Busby WH Jr, Duan C. Regulation of vascular smooth muscle cell responses to insulin-like growth factor (IGF)-I by local IGF binding proteins. J Biol Chem, 278:42886-42892, 2003.

202. Maile LA and Clemmons DR: The integrin associated protein binding domain of thrombospondin-1 enhances IGF-I receptor signaling in vascular smooth muscle cells. Circ Res, 93: 925-931, 2003.

21 203. Clemmons DR: The relative roles of growth hormone and IGF-1 in controlling insulin sensitivity. J Clin Invest 113:25-27, 2004.

204. Rosen CJ, Bitnell-Ackert CL, Adamo ML, Shultz KL, Rubin J, Donahue LR, Horton LG, Delahunty KM, Bramer WG, Sipos J, Clemmons DR, Nelson T, Bouxsein ML, Horowitz M: Congenic mice with low serum IGF-I have increased body fat, reduced bone mineral density and an altered osteoblast differentiation program. Bone, 35:1046-1058, 2004.

205. Gjustina A, Casanueva FF, Cavagnini F, Chanson P, Clemmons Dr, Frohman LA, Gaillard R, Ho K, Jaquet P, Kleinberg DL, Lamberts SW, Lombardi G, Sheppard M, Strasburger CJ, Vance ML, Wass JA, Melmed S. Diagnosis and treatment of acromegaly complications. J Endocrinol Invest 26:1242-1247, 2004.

206. Clemmons DR, Strasburger C. Monitoring the response to treatment in acromegaly. J Clin Endocrinol Metab 89:5289-5291, 2004.

207. Hou J, Clemmons Dr, Smeekens S: Expression and characterization of a serine protease that preferentially cleaves insulin-like growth factor binding protein-5. J Cell Biochem, 94:470-484, 2005.

208. Clemmons DR, Maile LA. Interaction between IGF-I receptor and alpha V beta 3 integrin linked signaling pathways: Cellular responses to changes in multiple signaling inputs. Mol Endocrinol, 19:1-11, 2005.

209. Moralez AM, Maile LA, Clarke J, Busby WH Jr, Clemmons DR: Insulin-like growth factor binding protein-5 (IGFBP-5) interacts with thrombospondin-1 to induce negative regulatory effects on IGF-I actions. J Cell Physiol, 203:328-334, 2005.

210. Ling Y, Maile LA, Badley-Clarke J, Clemmons DR: DOK1 mediates SHP-2 binding to the alphaVbeta3 integrin and thereby regulates insulin-like growth factor I signaling in cultured vascular smooth muscle cells. J Biol Chem, 280:3151-3158, 2005.

211. Ling Y, Maile LA, Leiskovska J, Badley-Clarke J, Clemmons DR: Role of SHPS-1 in the regulation of insulin-like growth factor-I (IGF-I) Stimulated Shc and MAP kinase activation in vascular smooth muscle cells. Mol Biol Cell, 16:3353-3360, 2005.

212. Clemmons DR, Moses AC, Sommer A, Jaccon W, Rogol AD: Rh/IGF-I/IGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose. Growth Horm IGF Res 15:265-274, 2005.

213. Barken AL, Burman P, Clemmons DR, Drake WM, Gagel RF, Harris PE, Trainer PJ, van der Lely AJ, Vance ML. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab 90:5684- 5691, 2005. 214. Clemmons DR, Sleevi M, Busby WH Jr. Recombinant, nonglycosylated human insulin- like growth factor binding protein-3 (IGFBP-3) is degraded preferentially after administration of type II diabetics, resulting in increased and endogenous glycosylated IGFBP-3. J Clin Metab 90:6561-6568, 2005. 215. Maile LA, Busby WH, Sitko K, Capps BE, Sergent T, Badley-Clark J, Clemmons DR. IGF-I signaling in smooth muscle cells is regulated by ligand binding to the 177CYDMKTTC184 sequence of the beta 3 subunit of the alpha V beta 3. Mol Endocrinol 20:405-413, 2005.

216. Ruan W, Fahlbusch F, Clemmons Dr, Monaco ME, Walden PD, Silva A, Schmid H, Kleinberg DL. SOM230 Inhibits IGF-I action in mammary gland development by pituitary independent mechanism: mediated through somatostatin subtype preceptor 3? Mol Endocrinol 20:426-436, 2006.

217. Kwon M, Ling Y, Maile LA, Badley-Clark J, Clemmons DR. Recruitment of the tyrosine phosphatase SHP-2 to the p85 subunit of phosphatidylinositol-3 (PI-3) kinase is required for insulin-like growth factor I dependent PI-3 kinase activation in smooth muscle cells. Endocrinol 147:1458-1465, 2006.

218. Maile LA, Busby WH, Sitko K, Capps BE, Sergent T, Badley-Clark J, Ling Y, Clemmons DR. The heparin-binding domain of vitronectin is the region that is required to enhance insulin-like growth factor-I signaling. Mol Endocrinol 20:881-892, 2006.

219. Pennisi P, Gavrilova O, Setser-Portas J, Jou W, Santopietro S, Clemmons DR, Yakar S, Leroith D Recombinant human insulin-like growth factor-I (rhIGF-I) treatment inhibits gluconeogenesis in a transgenic mouse model of type 2 diabetes mellius (DM). Endocrinol 147:2619-30, 2006.

220. Lievskovska J, Ling Y, Clark JB, Clemmons DR The role of Src kinase in insulin-like growth factor dependent mitogenic signaling in vascular smooth muscle cells. J Biol Chem. 281:25041-53, 2006.

221. Maile LA, Capps BE, Ling Y, Xi G, Clemmons DR Hyperglycemia alters the responsiveness of smooth muscle cells to insulin-like growth factor-I. Endocrinol, 148:2435-43, 2007.

222. Clemmons DR, Sleevi M, Allan G, Sommer A Effects of combined recombinant IGF-I and IGFBP-3 in type 2 diabetic patients on glycemic control and distribution of IGF-I and IGF- II among serum binding protein complexes. J Clin Endocrinol Metab 92:, 2652, 2658- 2007.

223. Miller EC, Capps BE, Sanghani RR, Clemmons DR, Maile LA: Regulation of IGF-I signaling in retinal endothelial cells by hyperglycemia. Invest Ophthalmol Vis Sci 48:3878-3887, 2007

224. Nichols TC, Busby WH Jr, Merricks E, Sipos J, Rowland M, Sitko K, Clemmons DR. Protease resistant IGFBP-4 inhibits IGF-I actions and neointimal expansion in a porcine model of neointimal hyperplasia. Endocrinol, 148:5002-5010, 2007.

225. Xi G, Maile LA, Yoo SE, Clemmons DR. Expression of the human beta3 integrin subunit in mouse smooth muscle cell enhances IGF-I stimulated signaling and proliferation. J Cell Physiol, 214:306-315, 2008.

226. Demambro VE, Clemmons DR, Horton LG, Bouxsein ML, Wood TL, Beamer WG, Canalis E, Rosen CJ. Gender specific changes in bone turnover and skeletal architecture in IGFBP-2-null mice. Endocrinol:149:2051-2061, 2008.

227. Maile LA, Capps BE, Miller EC, Allen LB, Veluvolu U, Aday A, Clemmons DR. Glucose regulation of integrin associated protein cleavage controls the response of vascular smooth muscle cells to insulin like growth factor-I. Mol Endocrinol 22:1226-1237, 2008.

228. Radhakrishnan Y, Maile LA, Ling Y, Graves LM, Clemmons DR. Insulin like growth factor-I stimulates Shc dependent PI-3 kinase activation via Grb-2 associated p85 in vascular smooth muscle cels. J Biol Chem 283:16320-16331, 2008.

229. Xi G, Shen X, Clemmons DR. p66Shc negatively regulates IGF-I signaling transduction via inhibition of p52shc binding to SHPS-1 leading to impaired Grb2 membrane recruitment. Mol Endocrinol 22:2162-2175, 2008.

230. Maile LA, Aday AW, Busby WH, Sanghani R, Veluvolu U, Clemmons DR. Modulation of integrin-antagonist signaling by ligand binding of the heparin-binding domain of vitronectin to the alphaVbeta3 integrin. J Cell Biochem 105:437-446, 2008.

231. Maile LA, Capps BE, Miller EC, Aday AW, Clemmons DR. IAP association with SHPS-1 regulates IGF-I signaling in vivo. Diabetes 57:2637-2643, 2008.

232. Jimenez C, Burman P, Abs R, Clemmons D, Drake W, Hutson K, Messig M, Thorner M, Trainer P, Gagel R. Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials. Eur J Endocrinol 159:517-23, 2008

233. Busby WH Jr, Yocum SA, Rowland M, Kellner D, Lazerwith S, Sverdrup F, Yates M, Radabaugh M, Clemmons DR. Complement 1s is the serine protease that cleaves IGFBP-5 in human osteoarthritic joint fluid. Osteroarthritis Cart 17:547-555, 2009.

234. Webb SM, Strasburger CJ, Mo D, Hartman ML. Melmed S, Jung H, Blum SF, Attanasio AF; HypoCCS International Advisory Board. Changing pathway of adult growth hormone deficiency diagnosis documented in a decade long global surveillance database. J Clin Endocrinol Metab 94:392-399, 2009

235. Yakar S, Rosen CJ, Bouxsein ML, Sun H, Mejia W, Kawashima Y, Wu Y, Emerton K, Williams V, Jepsen K, Schaffler MB, Majeska RJ, Gavrilova O, Gutierrez M, Hwang D, Pennisi P, Frystyk J, Boisclair Y, Pintar J, Jasper H, Domene H, Cohen P, Clemmons D, Leroith D: Serum complexes of insulin-like growth factor-1 modulate skeletal integrity and carbohydrate metabolism. FASEB J 23:709-19, 2009

236. Allen LB, Capps BE, Miller EC, Clemmons DR, Maile LA. Glucose oxidized low-density lipoproteins enhance IGF-I stimulated smooth muscle cells proliferation by inhibiting integrin associated protein cleavage. Endocrinol 150:1321-9, 2009

237. Shen X, Xi G, , Radhakrishnan Y, Clemmons DR. Identification of novel SHPS-1 association protein and their roles in the regulation of insulin-like growth factor- dependent responses in vascular smooth muscle cells. Mol Cell Proteomics, 8:1539-51, 2009

238. Woodmansee WW, Hartman ML, Lamberts SW, Zagar AJ, Clemmons DR. Occurrence of impaired fasting glucose in GH-deficient adults receiving GH replacement compared to untreated subjects. Clin Endocrinol 72:59-69, 2009.

239. Fazeli PK, Bredella MA, Misra M, Meenaghan E, Rosen CJ, Clemmons DR, Breggia A, Miller KK, Klibanski A. Predipocyte Factor-1 is associated with marrow adiposity and bone mineral density in women with anorexia nervosa. J Clin Endocrinol 95:407-13, 2009.

24 240. Fritton JC, Kawashima Y, Mejia W, Courtland HW, Elis S, Sun H, Wu Y, Rosen CJ, Clemmons D, Yakar. The insulin-like growth factor-1 (IGF-1) binding protein acid-labile subunit (ALS) alters mesenchymal stromal cell fate. J Biol Chem 285:4709-14, 2010.

241. Xi G, Shen X, Clemmons DR. p66Shc inhibits IGF-I signaling via direct binding to Src through its polyproline and SH2 domains resulting in impairment of Src kinase activation. J Biol Chem 285:6937-51, 2010.

242. Maile LA, Allen LB, Veluvolu U, Capps BE, Busby WH, Rowland M, Clemmons DR. Identification of compounds that inhibit IGF-I signaling in hyperglycemia. Exp Diabetes Res 2009:267107, 2010.

243. Maile LA, Busby WH Jr, Nichols TC, Bellinger DA, Merricks EP, Rowland M, Veluvolu V, Clemmons DR. A monoclonal antibody againαVβ3 integrin inhibits development of atherosclerotic lesions in diabetic pigs. Sci Trans Med 2:62-69, 2010.

244. Radhakrishnan Y, Busby WH Jr, Shen X, Maile LA, Clemmons DR. Insulin-like growth factor-1 (IGF-I) stimulated insulin receptor substrate-1 negative regulates Src homology 2 domain-containing protein-tyrosine phosphatase substrate-1 function in vascular smooth muscle cells. J Biol Chem 285:15682-95, 2010.

245. Ning J, Clemmons DR. AMP-activation protein kinase inhibits IGF-I signaling and protein synthesis in vascular smooth muscle cells via stimulation of insulin receptor substrate 1 S794 and tuberous sclerosis 2 S1345 phosphorylation. Mol Endocrinol 24:1218- 29, 2010.

246. Kawai M, Green CB, Lecka-Czernik B, Douris N, Gilbert MR, Kojima S, Ackert-Bicknell C, Garg N, Horowitz MC, Adamo ML, Clemmons DR, Rosen CJ. A circadian-regulated gene, Nocturnin, promotes adipogenesis by stimulating PPAR-gamma nuclear translocation. Proc Natl Acad Sci USA 107:10508-13, 2010.

247. Shen X, SiG, Radhakrishnan Y, Clemmons DR. Recruitment of Pyk2 to SHPS-1 signaling complex is required for IGF-I-dependent mitogenic signaling in vascular smooth muscle cells. Cell Mol Life Sci, 67:3893-3903, 2010.

248. Xi G, Shen X, Radhakrishnan Y, Maile L, Clemmons DR. Hyperglycemia-induced p66Shc inhibits insulin-like growth factor-I dependent cell survival via impairment of Src kinase- mediated phosphoinositide-3 kinase/AKT activation in vascular smooth muscle cells. Endocrinol 151:3611-3623, 2010.

249. Maile LA, Allen LB, Hanzaker C, Gollahon K, Dunbar P, Clemmons DR. Glucose regulation of thrombospondin and its role in modulation of smooth muscle cell proliferation. Exp Diabetes Res, 2010:p11617052.

250. Shen X, Xi G, Radhakrishnan Y, Clemmons DR. PDK1 recruitment to the SHPS-1 signaling complex enhances IGF-I stimulated AKT activation and vascular smooth muscle cell survival. J Biol Chem 285:29416-29424, 2010.

251. Fazeli PK, Lawson EA, Prabhakaran R, Miller KK, Donoho DA, Clemmons DR, Herzog DB, Misra M, Klibanski A. Effects of recombinant human growth hormone in anorexia nervosa: a randomized, placebo-controlled study. J Clin Endocrinol Metab 95:4889-4897, 2010.

252. Cascella T, Radhakrishnan Y, Maile LA, Busby WH Jr, Gollahon K, Colao A, Clemmons DR. Aldosterone enhances IGF-I-mediated signaling and biological function in vascular smooth muscle cells. Endocrinol 151:5851-5864, 2010

253. Kawai M, Breggia AC, DeMambro VE, Shen X, Canalis E, Bouxsein ML, Beamer WG, Clemmons DR, Rosen CJ. The heparin-binding domain of IGFBP-2 has insulin-like growth factor binding-independent biologic activity in the growing skeleton. J Biol Chem 286:14670-14680, 2011.

254. Attanasio AF, Jung H, Mo D, Chanson P, Bouillon R, Ho KK, Lambert SW, Clemmons DR. Prevalance and incidence of diabetes mellitus in adult patients on growth hormone replacement for growth hormone deficiency. J Clin Endocrinol 96:2255-2261, 2011.

255. Zhong Y, Lu L, Zhou J, Li Y, Liu Y, Clemmons DR, Duan C. IGF binding protein-3 exerts its ligand-independent action by antagonizing BMP in zebrafish embryos. J Cell Sic 12:1925-1035, 2011.

256. Maile LA, DeMambro VE, Wai C, Aday AW, Capps BE, Beamer WG, Rosen CJ, Clemmons DR. An essential role for the association of CD47 to SHPS-1 in skeletal remodeling. J Bone Miner Res 26:2068-2081, 2011.

257. Ning J, Xi G, Clemmons DR. Suppression of AMPK activaiotn via S485 phosphorylation by IGF-I during hyperglycemia is mediated by AKT activation in vascular smooth muscle cells. Endocrinol 152:3143-3154, 2011.

258. Radhakrishnan Y, Shen X, Maile LA, Xi G, Clemmons DR. IGF-I stimulates cooperative interaction between the IGF-I receptor and CSK homologous kinase that regulates SHPS- 1 phosphorylation in vascular smooth muscle cells. Mol Endocrinol 25:1636-1649, 2011.

Nonrefereed:

l. Van Wyk JJ, Hintz RL, Clemmons DR, Hall K, Uthne K: Human somatomedin, the growth hormone dependent sulfation/thymidine factor. Proceedings of the 4th International Congress of Endocrinology. Excerpta Medica. Amsterdam, pp. l3l6-l319, 1973.

2. Van Wyk JJ, Underwood LE, Baseman JB, Hintz RL, Clemmons DR, Marshall RN: The somatomedins: A family of insulin-like hormones under growth hormone control. Rec. Prog. Horm. Res. 30:259-3l8, 1974.

3. Van Wyk JJ, Underwood LE, Baseman JB, Hintz RL, Clemmons DR, Marshall RN: Explorations of the insulin-like and growth promoting properties of somatomedin. Adv. Metab. Disord. 8:l27-l43, 1975.

4. Underwood LE, Copeland KC, Clemmons DR, Chatelain PG, Blethen SL, Van Wyk JJ: Radioimmunoassay of somatomedin-C: Clinical applications. In Walkhausl WK (ed) Diabetes. Excerpta Medica, Amsterdam, pp. 278-289, 1979.

5. Van Wyk JJ, Underwood LE, Svoboda ME, Clemmons DR, Klapper DT, Fellows RE: Somatomedin-C: Chemistry and biology. In Pecile A. Muller E (eds). Growth

26 Hormones and Other Biologically Active Peptides. Excerpta Medica, Amsterdam, pp. 73- 9l, 1980.

6. Van Wyk JJ, Underwood LE, D'Ercole AJ, Clemmons DR, Pledger WJ, Leof EB: Role of somatomedin in cellular proliferation. In Ritzen EM (ed), Biology of Normal Human Growth. Raven Press, pp 84-99, 1980.

7. D'Ercole AJ, Underwood LE, Clemmons DE, Svoboda ME, Van Wyk JJ: Somatomedin-C: Molecular structure biological actions and role in postnatal and fetal growth. In Cumming IA, Funder JW, Mendelsohn FAP (eds), Endocrinology. Australian Academy of Science. Canberra, pp. 2l5-235, 1980.

8. Underwood LE, Clemmons DR, D'Ercole AJ, Minuto F, Chatelain PG, Copeland KC, Van Wyk JJ: Somatomedin-C: Measurement by radioimmunoassay, regulatory mechanisms in humans and uses in clinical diagnosis. Bull. Swiss Acad. Med., pp. 141-166, 1982.

9. Underwood LE, Clemmons DR, Van Wyk JJ, Chatelain PG, Copeland KC: Plasma immunoreactive somatomedin-C/IGF-I in the evaluation of short stature. In Spencer EM (ed) Insulin-like growth factors/Somatomedin: Basic chemistry, biology and clinical importance. Walter deGruyter and Co., Berlin, pp. 235-254, 1983.

10. Underwood LE, Van Wyk JJ, D'Ercole AJ, Clemmons DR, Svoboda ME: Physiology of somatomedin-C/insulin-like growth factor I. In Labrie F, Proulx L (eds) Endocrinology, Excerpta Medica, Amsterdam, pp. 480-483, 1985.

11. Clemmons DR, Underwood LE: Use of plasma somatomedin-C measurements to monitor the response to nutritional repletion. In Hintz RL, Underwood LE (eds) Somatomedins and other growth factors: Relevance to pediatrics. Proceedings of the 89th Ross Conference on Pediatric Research. Ross Laboratories, Columbus OH, pp. 56- 63, 1985.

12. Underwood LE, Smith EP, Van Wyk JJ, Clemmons DR, D'Ercole AJ, Pandian MR, Preece MA, Moore WV: Somatomedin-C/insulin-like growth factor I: Regulation and clinical applications. In Raiti S (ed) Human Growth Hormone, Plenum Publishing Corp., NY, pp. l4l-l80, 1986. l3. Clemmons DR, Underwood LE, Van Wyk JJ: Somatomedin-C/insulin-like growth factor I: Regulation by growth hormone and nutrients and production by cultured cells. Proceedings of International Congress of Endocrinology, Molinatti and Martini (eds). Elsevier, North Holland, pp. l0l-ll3, 1986. l4. Clemmons DR: Assessment of nutritional status by measurement of somatomedin- C/insulin-like growth factor I. Proceedings of the International Diabetes Federation. Serrano-Rios (ed). Elseview, North Holland, pp. 244-250, 1986. l5. Underwood LE, Clemmons DR, Maas M, D'Ercole AJ, Ketelschegers JM: Regulation of somatomedin-C/insulin-like growth factor I by nutrients. Hormone Research 24:l66-l76, 1986. l6. Clemmons DR, Underwood LE: Growth hormone as a potential adjunctive therapy for weight loss in human growth hormone progress and challenges. Underwood LE (ed). Marcel Decker, NY, pp. 207-2l8, 1987.

27 l7. Clemmons DR, Dehoff M, McCusker R, Elgin RG, Underwood LE, Busby WH: The role of insulin-like growth factor I in the regulation of growth. J. Ani. Sci. Suppl.2:l68-l79, 1988. l8. Clemmons DR, Busby WH, Underwood LE: Mediation of the growth promoting actions of growth hormone by Sm-C/IGF-I and its binding protein. Anal. of Hum. Biol. l4:455- 459, 1988.

19. Clemmons DR, Snyder DK, Underwood LE: Interaction of growth hormone and nutritional intake in facilitating nitrogen conservation and promoting lipolysis. In: Bercu B (ed) Basic and Clinical Aspects of Growth Hormone, Plenum Press, New York, pp. 347- 356, 1988.

20. Clemmons DR, Snyder DK, Underwood LE: The control of somatomedin-C/insulin-like growth factor I concentrations in humans. In: Jones CT (ed) Fetal and Neonatal Development. Perinatology Press, Ithica, NY, pp. 622-630, 1988.

21. Underwood LE, Smith EP, Clemmons DR, Maes M, Maiter D, Kettelselegers JM: The production and action of insulin-like growth factors: Their relationship to nutrition and growth. In: Tanner JM (ed) Auxology 1988 Smith Gordon, London, pp. 235-249, 1989.

22. Clemmons DR: Insulin-like growth factor binding proteins: Structural analysis and mechanisms of action. Growth and Growth Factors, Current Medical Literature 4:3-7, 1989.

23. Clemmons DR: Structural and functional analysis of insulin-like growth factors. Brit. Med. Bull. 45:465-480, 1989.

24. Clemmons DR: Role of insulin-like growth factor binding proteins in controlling the expression of IGF actions. In: Raizada MK (ed) Molecular and Cellular Biology of Insulin-like Growth Factors and Their Receptors, Plenum, New York, pp. 381-394, 1989.

25. McCusker RH, Busby WH, Hubner CC, Clemmons DR: Secretion of insulin-like growth factor binding proteins (IGF-BP's) by muscle-cells in vitro. In: Insulin-like Growth Binding Proteins, Elsevier, New York NY, pp. 257-266, 1990.

26. Hill DJ, Han VKM, Clemmons DR, Camacho-Hubner C, Wary JF: Expression distribution release and biological action of insulin-like growth factor binding proteins during development. In Hinton L and Drop SL (eds) Insulin-like Growth Factor Binding Proteins. Elsevier, New York, NY, pp. 55-64, 1990.

27. Clemmons DR: Control of IGF action by IGF binding proteins. Trends in Endocrinology and Metabolism. Elsevier, 1:412-418, 1990.

28. Osborne CK, Clemmons DR, Artega CL: Regulation of breast cancer growth by insulin- like growth factors. J. Steroid Biochem. Molecular Biol. 37:805-809, 1990.

29. Clemmons DR: Role of peptide growth factors in the macrovascular complications of diabetes. Diabetes Care, 14:153:156, 1991.

28 30. Clemmons DR: Insulin-like growth factor binding proteins: roles in regulating IGF physiology. J. Devel. Physiol., 15:105-110, 1991.

31. Clemmons DR, Camacho-Hubner C, Jones JI, McCusker RH, Busby WH: Insulin-like growth factor binding proteins: Mechanisms of action at the cellular level. Spencer EM (ed) Modern Concepts of Insulin-like Growth Factors, Elsevier, New York, NY, pp. 475- 487, 1991.

32. Clemmons DR: Insulin-like growth factor binding proteins. Henry HL, Norman AN (eds.), Proceedings of the 14th Annual Symposium in Molecular and Cellular Endocrinology, 1991.

33. Underwood LE, Clemmons DR, Moats-Staats DM, D'Ercole AJ, Maes M, Maiter D, Thissen JP, Ketelschlegers JM: Nuitrition and Hormone Regulation of Growth in Nutritional Needs of Six to Twelve Month Old Infants. Heird WC (ed), Glendale Raven Press, NY, Vol. 2:49-66, 1991.

34. Clemmons DR: Functional Properties of IGF Binding Proteins. In: Molecular and Cellular Biology of Insulin-like Growth Factors and Their Receptors. Raizada M (ed.), Plenum, New York, NY, 293:113-124, 1991.

35. Clemmons DR: Role of insulin-like growth factor-I in reversing catabolism. J. Clin. Endo. Metab. 75:1183-1185, 1992.

36. Clemmons DR: Insulin like growth factor binding proteins. In Proceedings of the International Diabetes Federation, 35:114-119, 1992.

37. Clemmons DR and Underwood LR: Role of Growth Hormone and IGF-I in stimulating the anabolic response. Proceedings of a workshop on age-related changes in musculoskeletal soft tissue, Plenum, New York, pp. 141-149, 1993.

38. Cohick WS and Clemmons DR: Regulation of IGFBP secretion and modulation of cell growth in MDBK cells. Growth Regulation 3:20-23, 1993.

39. Jones JI, Busby WH, Wright G, Clemmons DR: Human IGFBP-1 in phosphorylated in serine residues: effects of site directed mutagenesis of the major phosphoserines. Growth Regulation 3:37-40, 1993.

40. Walker J, Baxter RC, Young S, Pucilowska J, Clemmons DR, Underwood LE: Effects of recombinant IGF-I on IGF binding proteins and the acid labile subunit (ALS) in growth hormone in sensitivity syndrome. Growth Regulation 3:109-112, 1993.

41. LeRoith D, Adamo M, Roberts CT, Clemmons DR, Sheikh S, Shao Z, Clen JC, Fontana JA: Retnoic acid inhibits growth of breast cancer cell lines, the role of insulin like growth factor binding proteins. Growth Regulation 378-80, 1993.

42. Clemmons DR: The role of insulin like growth factor binding proteins in modulating IGF action. Proceedings of the 7th International Symposium on Growth Hormone.

43. Underwood LE, Clemmons DR, Kupfer S, Walker JL, Van Wyk JJ: Potential therapeutic uses of IGF-I. Presented to the 7th International Symposium on Growth Hormone.

29 44. Clemmons DR: IGF binding proteins and their functions. Molecular Reproduction and Development. 35:368-377, 1993.

45. Clemmons DR, Underwood LE: Effects of growth hormone and insulin like growth factor I in adults made catabolic by energy restriction. In Molecular and Clinical Advances in Pituitary Disorders. Endocrine Research and Education Inc., Beverly Hills, CA, pp. 165-172, 1993.

46. Clemmons DR: Role of post translational modifications in modifying the biologic activity of insulin like growth factor binding proteins. Advances in Experimental Medicine and Biology, Plenum Press, New York, 343:245-254, 1993.

47. Clemmons DR, Jones JI, Busby WH, Wright G: Role of insulin like growth factor binding protein in modifying IGF actions. Ann. NY Acad. Sci. 692:10-21, 1993.

48. Clemmons DR, Underwood LE: Role of insulin like growth factors and growth hormone reversing catabolic states. Horm. Res. 38 Suppl. 2:37-40, 1994.

49. Clemmons DR: Use of Growth Hormone and insulin like growth factor-I in catabolism that is induced by negative energy balance. Horm. Res. 40:62-67, 1994.

50. Bondy CA, Underwood LE, Clemmons DR, Guler HP, Bach MA: Clinical uses of insulin like growth factor-I. NIH Conference. Ann. Inter. Med., 120:593-601, 1994.

51. Armstrong TD, Stanko RL, Cohick WE, Simpson BB, Harvey RW, Huff BG, Clemmons DR, Whitacre MD, Cambell RM, Heiner EP: Endocrine events prior to puberty in heifers: role of somatotropin, insulin like growth factor I and insulin like growth factor binding proteins: J. Physiol. Pharm. 43, Suppl. 41:179-193, 1994.

52. Clemmons DR, Underwood LE: Uses of human insulin like growth factor I in clinical conditions. J. Clin. Endo. Metab., 79:4-7, 1994.

53. Clemmons DR, Nam TJ, Busby WH, Parker A: Modification of IGF actions by insulin- like growth factor binding protein-5. In Insulin-like Growth Factors and Their Regulatory Proteins. (eds) Baxter RC, Gluckman PD, Rosenfeld RG. Exerpta Medica, Amsterdam, 1994, pp. 183-192.

54. Underwood LE, Clemmons DR: Prospects of therapy with IGF-I for catabolic conditions. In Insulin-like Growth Factors and Their Regulator Proteins. (eds) Baxter RC, Gluckman PD, Rosenfeld RG. Exerpta Medica, Amsterdam, 1994, pp. 449-456.

55. Clemmons DR: Growth hormone and IGF-I as anabolic partitioning hormones. In The Somatotrophic Axis and the Reproductive Process in Health and Disease. (eds) Adashi EY and Thorner MO. Springer Verlag, New York, 1994, pp 58-68.

56. Underwood LE, Thissen JP, Lenozy S, Ketelsleggers JM, Clemmons DR: Hormonal and nutritional regulation of IGF-I and its binding proteins. Hormone Research, 42:145-511, 1994.

57. Clemmons DR: Regulation of IGF actions by IGFBP-3. LeRoith D and Raizada M (eds). Advances in Experimental Medicine and Biology 373:232-240, 1995.

58. Clemmons DR, Busby WH, Clark J, Duan C, Arai T, Nam TJ: Insulin-like growth factor binding proteins and their role in controlling IGF actions. In The Role of Insulin-like Growth Factors in Ovarian Physiology. (ed) LeRoith D. Frontiers in Endocrinology 19:13-24, 1995.

59. Clemmons DR: IGF-I therapy in Type II Diabetes in Growth Hormone and IGF Action. (ed) GunnersonR, Springer Verlag, Berlin, 1995, pp. 119-127.

60. Jones JI, Doerr ME, Clemmons DR: Cell migration: interactions among integrins, IGFs and IGFBPs. (eds) Blum W, Hall K. In Progress in Growth Factor Res 6:319-327, 1995.

61. Clemmons DR, Busby WH, Arai T, Nam TJ, Clarke JB, Jones JI, Ankrapp DK: Role of insulin-like growth factor binding proteins in the control of IGF actions. (eds) Blum W, Hall K. In Progress in Growth Factor Research 6:357-366, 1995. 62. Morrow LA, O’Brien M, Clemmons DR, Moses AC: Recombinant human insulin-like growth factor-I improves insulin sensitivity in diabetes. Diabetes Care 18:1065-71, 1995.

63. Clemmons DR, Moses AC, Young CJS, Morrow LA, O’Brien MA: Insulin sensitivity is increased in Type II diabetes mellitus in response to human insulin-like growth factor-I. Endocrinol and Metab 3:(supplement A) 83-89, 1996.

64. Clemmons DR: Interaction between IGF-I, insulin and growth hormone in Type II diabetes. J Ped Endocrinol and Metab, 10:97-104, 1997.

65. Clemmons DR, Imai Y, Zheng B, Clarke J, Busby WH: Regulation of insulin-like growth factor-I actions by insulin-like growth factor binding protein-5. Proceedings of the 4th International Symposium on Insulin-like Growth Factors, Elsevier, Amsterdam. Tokyo, Japan, 21-24 October 1997, pp. 115-124.

66. Clemmons DR, Busby WH, Clarke JB, Parker A, Duan C, Nam TJ: Modifications of insulin- like growth factor binding proteins and their role in controlling IGF actions. Endocrine Journal 45:(supplement) S1-S8, 1998.

67. Baxter RC, Binoux MA, Clemmons DR, Cononver CA, Drop SL, Holly JM, Mohan S, Oh Y, Rosenfeld RG. Recommendations for nomenclature of the insulin like growth factor binding protein superfamily. J Clin Endo Metab 83:3213, 1998.

68. Klibanski A, Clemmons DR, Christiansen J, Underwood LE: Growth hormone replacement therapy in adults: the changing role of growth hormone therapy. Endocrine Practice 5:88-96, 1999.

69. Clemmons DR: The diagnostic use of IGF-I and insulin-like growth factor binding protein measurements in growth hormone deficiency. Hormone Res, 45:651-658, 2000.

70. Barkan A, Clemmons DR, Molich M, Stewart P, Young W: Growth hormone therapy for pituitary adults: time for reappraisal. Trends in Endocrinology and Metabolism, 11:155- 166, 2000.

71. Clemmons, DR: Commercial assays available for insulin-like growth factor-I and their use in growth hormone deficiency, Hormone Res 55 (suppl2) 73-79, 2001

31 72. Ranke MB, Feldt- Rassaussa U, Bang P, Baxter RC, Camacho-Hubner C, Clemmons DR, Juul A, Orskov H, Strassburger CJ. How should insulin-like growth factor-I be measured? A consensus statement. Hormone Res 55 Suppl 2 106-109, 2001.

73. Clemmons, DR: IGF-I receptor mediated signal transduction. Targets for Growth Hormone and IGF-I Action. Bouillon, R(ed); BioScientifica, Bristol UK. Vol 5 pp 17-29, 2001

74. Klibanski, A, Ho K, Freda P, Clemmons DR, Boytran A, Kleinberg DL, Trainer P, Swearinger B, Molitch M, Wass JH, Thorner MO, Melmed S, Strasburger C, Frohman LA: State of the art strategies for diagnosis and management of acromegaly, in press

75. Clemmons, DR, O’Connel, T, Zheng, B and Busby, WH: Prediction of growth hormone and IGF-I actions through autocrine/paracine and endocrine mechanisms. DL Kleinberg and DR Clemmons (eds); BioScientifica, Bristol UK. Vol 6 pp 199-213, 2002.

76. Clemmons DR: Role of insulin-like growth factor I and growth hormone in mediating insulin resistance in acromegaly. Pituitary 5:181-183, 2002.

77. Clemmons, DR: Modulation of insulin-like growth factor I actions by IGF-binding proteins. Strassburger C (ed) BioScientifica Bristol, UK . Vol 7, pp 163-175, 2003.

78. Clemmons DR: Role of insulin-like growth factor in maintaining normal glucose homeostasis. Horm Res 1:77-82, 2004

79. Molitch ME, Clemmons DR, Malozowski S, Marriam GR, Shalet SM, Vance ML: Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 91:1621-1634, 2006

80. Clemmons DR, Maile LA, Ling Y, Yarber J, Busby WH: Role of the integrin alphaVbeta3 in mediating increased smooth muscle cell responsiveness to IGF-I in response to hyperglycemic stress. Growth Horm IGF-I Res 17L265-270, 2007.

81 Clemmons DR: IGF-I and the regulation of the cell cycle in hormonal control of the cell cycle. Melmed S and Chasson P (eds) Springer, Berlin Germany pp41-49, 2007.

82. Clemmons DR: Long-acting forms of growth hormone-releasing hormone and growth hormone: effects in normal volunteers and adults with growth hormone deficiency. Horm Res 68 suppl5:178-181, 2007.

83. Giustina A, Barkan A, Chanson P, Grossman A, Hoffman A, Ghigo E, Casanueva F, Colao A, Lamberts S, Sheppard M, Melmed S. Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults. J Endocrinol Invest 31:820- 838, 2008.

84. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A: Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94:1509-1517, 2009.

85. Klibanski A, Melmed S, Clemmons DR, Colao A, Molitch ME, Vinik A, Adelman DT, Liebert RJ. The Endocrine tumor summit 2008: apprasing therapeutic approaches to acromegaly and carcinoid syndrome. Pituitary 13:266-86, 2010.

86. Clemmons DR. Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clin Chem 57:555-559, 2011.

87. Clemmons DR. AMP kinase signals the insulin-like growth factor system whether adequate nutrient is present to support an anabolic response. Cell Cycle 10:1017-1018, 2011.

88. Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML. Evaluation and treatment of adult growth hormone deficiency; an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96:1587-1609, 2011.

Reviews and Book Chapters:

1. Clemmons DR, Van Wyk JJ: Somatomedin: Physiological control and effects on cell proliferation. In Baserga R (ed) Handbook of Experimental Pharmacology. Springer- Verlag, New York, pp. l6l-208, 1982.

2. Clemmons DR, Van Wyk JJ: Factors controlling blood concentration of somatomedin-C. In Daughaday WH (ed) Clinics Endocrinol Metab. W. H. Saunders Co., Philadelphia, PA, l3:ll3-l43, 1984.

3. Clemmons DR: Steroid therapy and withdrawal. In Fletcher R (ed) Primary Care Internal Medicine. Little Brown, Boston, MA, pp. l26-l34, 1985.

4. Underwood LE, D'Ercole AJ, Clemmons DR, Van Wyk JJ: Paracrine functions of somatomedins. In Frachimont D (ed). Clinics Endocrinol Metab. W. H. Saunders Co., Philadelphia, l5:59-77, 1986.

5. Clemmons DR, Underwood LE: Somatomedin-C/insulin-like growth factor I in acromegaly. In Besser GM (ed) Clinics in Endocrinology Metab, l5:629-653, 1986.

6. Clemmons DR: Growth factors and somatomedins in Kelley WN (ed) Textbook of Internal Medicine. JB Lippincott, Philadelphia, Vol. l:2l28-2l30, 1989.

7. Clemmons DR: Insulin like growth factor binding proteins 1: 412-418, 1990.

8. Clemmons DR: Insulin-like growth factor binding proteins. In LeRoith D (ed), Insulin- like Growth Factors, Insulin-like Growth Factor Binding Proteins: Molecular and Cellular Aspects, CRC Reviews, Boca Raton, pp. 151-181, 1991.

9. Clemmons DR: Growth factors and somatomedins in Kelley WN (ed) Textbook of Internal Medicine. JB Lippincott, Philadelphia, PA, Vol. 2: 2nd Edition, pp 846-1249, 1991.

10. Clemmons DR, Underwood LE: Nutritional regulation of IGF-I and IGF binding proteins. Ann Review Nutr. 11:393-412, 1991.

11. McCusker RH and Clemmons DR: The insulin-like growth factor binding proteins structure and biologic action in Schofield P (ed), The Insulin-like Growth Factor, Structure and Biologic Functions, Oxford Press, Oxford England, pp 110-150, 1992.

33 12. LeRoith D, Clemmons DR, Nissley SP, Rechler MM: Insulin-like growth factors in health and disease. Ann Int. Med. 116:854-862, 1992.

13. Clemmons DR: Corticosteroid therapy and withdrawal in Dornhard L(ed) Manual of clinical problems in adult ambulatory care. Little Brown 2nd edition, pp 437-443, 1992.

14. Clemmons DR: IGF binding proteins: Regulation of Cellular actions. Growth Regulation 2:80-88, 1992.

15. Cohick WS, Clemmons DR: The insulin-like growth factors, Ann. Rev Physiol, 55:131-153, 1993.

16. Clemmons DR: Peptide Growth Factors in Kahn CR and Weir CG (eds) Joslin Textbook of Diabetes, Lea & Fabringer, 6th edition pp 348-361, 1995.

17. Jones JI, Clemmons DR: Insulin-like growth factors and their binding proteins: Biological actions. Endocrine Reviews, 16:3-34, 1995.

18. Clemmons DR: Insulin-like growth factor binding proteins. In LeRoith D and Bondy CA (eds.) Growth Factors and Cytokines in Health and Disease, JAI Press, Greenwich, CT, Vol 3A, pp. 185-217, 1996.

19. Clemmons DR: Insulin-like growth factor binding proteins and their role in controlling IGF actions in, Cytokine and Growth Factor Reviews. (eds) Vilcek J, Sporn MB, Elsevier, Oxford 8:45-62, 1997.

20. Clemmons DR: Usefulness of IGFs and IGFBPs in the diagnosis of Disease. In Current Opinions of Endocrinology and Diabetes. (ed.) Kahn CR. Rapid Science, Philadelphia. 4:26-35, 1997.

21. Clemmons DR: Growth factors in atherosclerosis. Diabetes Rev 5:353-364, 1997.

22. Rechler MM, Clemmons DR: Regulatory actions of insulin-like growth factor binding proteins. In Catt K (ed), Trends in Endocrinology and Metabolism, Elsevier, New York, Vol 9, 176-183, 1998.

23. Carroll PV, Christ ER, Bengtsson BA, Carlsson L, Christensen JS, Clemmons DR, Hintz R, Hok Lamm Z, Zizonenko P, Sonksen PH, Tanaka T, Thorner MO: Growth hormone deficiency in adulthood and effects of growth hormone replacement: a review. J Clin Endocrinol Metab 83:382-95, 1998.

24. Clemmons DR: Insulin-like growth factor binding proteins. In Kostyo J (ed.), Handbook of Physiology, Hormonal Control of Growth, Oxford University Press, New York, 5:573- 632, 1999.

25. Clemmons DR: Regulation of insulin-like growth factor-I and its role in controlling growth and metabolism. In Bentsson BA (ed.), Growth Hormone Endocrine Update Series, Kluwer Academic Publishers, Norwell, MA, Vol. 4, 59-76, 1999.

26. Clemmons DR: IGF binding proteins and extracellular matrix. In The IGF System: Molecular Biology, Physiology, and Clinical Applications. Roberts CR, Rosenfeld R (eds.), Humana Press, Totowa, NJ 273-280, 1999.

27. Zheng B, Clemmons DR: Methods for preparing extracellular matrix and quantifying insulin-like growth factor binding proteins. In Methods in Molecular Biology, vol. 139: Extracellular matrix protocols. Streidi C. and Grant M. (eds.), Humana Press, Totowa, NJ, 1-10, 1999.

28. Klibanski A, Clemmons DR, Christensen J, Underwood LE: Growth hormone replacement therapy for growth hormone deficient adults: The changing role of growth hormone therapy. Endocrine Practice 5:88-96, 1999

29. Clemmons DR: Insulin-like growth factor-1 and its binding proteins. Textbook of Endocrinology. DeGroot LJ and Jamison JL (eds.), W.B. Saunders, Philadelphia, PA, pp. 439-460, 2000.

30. Clemmons DR: Insulin-like growth factors: Their binding proteins and growth regulation.In Skeletal Growth Factors. Canalis E. (ed), Lippincott Williams & Wilkins, Philadelphia, PA, pp. 79-100, 2000.

31. Cohen P, Clemmons DR, Rosenfield RG: Does the GH/IGF axis play a role in cancer pathogenesis? Growth Hormone and IGF Research 10:297-305, 2000

32. Clemmons DR: Insulin-like growth factor-I physiology. Up to Date, 2001.

33. Simpson H, Savine R, Sonksen P, Bengtsson BA, Carlsson L, Christiansen JS, Clemmons D, Cohen P, Hintz R, Ho K, Mullis P, Robinson I, Strasburger C, Tanaka T, Thorner M: The GRS Council. Growth hormone replacement therapy for adults: into the new millennium. Growth Hormone and IGF Research 12 (1):1-33, 2002.

34. Clemmons DR: Pituitary disease. Netter Textbook of Medicine. Runge M,Greganti A (eds), Icon Publication Teterboro, NJ pp256-264,2003.

35. Clemmons DR: Role of insulin-like growth factor I and extracellular matrix protein interaction in controlling cellular responses to this growth factor. In Insulin-like Growth Factors. LeRoith D , Zumkeller W, and Baxter RM (eds),Klewer/Academic Plenum, New York, PP498-537, 2003.

36. Clemmons DR and Maile LA: Minireview: Integral membrane proteins that function coordinately with the insulin-like growth factor I receptor to regulate intracellular signaling. Endocrinology 144:1664-1670, 2003.

37. Clemmons, DR, Chihara K, Freda PU, Ho KK, Klibanski A, Melmed S, Shalet SM, Starsburger CJ, Trainer PJ, Thorner MO: Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm. J Clin Endocrinol Metab 88:4759-4767, 2003.

38. Clemmons DR, Runge M: Cardiovascular manifestations of Endocrine Diseases. Netter Textbook of Cardiology. Runge M, Ohman M eds, Icon Publications Teterboro NJ, pp528- 542, 2004.

39. Clemmons DR, Strasburger C: Monitoring the response to treatment in acromegaly. J Clin Endocrinol Metab. 89:5289-91, 2004.

35 40. Clemmons DR: Diabetes mellitus: An important cardiovascular risk factor. In Molecular Cardiology. Runge Ms, Patterson C (eds), Human Press, Totowa NJ, pp563- 576, 2005.

41. Clemmons, DR: Role of insulin-like growth factor-I and management of acromegaly. Endo Pract 10:362-371, 2005.

42. Cianfarani S, Clemmons DR, Savage MO (eds): IGF-I and IGF binding proteins. Basic Research and Clinic Management Vol 9, pp 301-307, 2005.

43. Clemmons DR: Quantitative measurement of IGF-I and its use in diagnosing and monitoring treatment of disorders of growth hormone secretion. Endocr Dev 9:55-65, 2005.

44. Clemmons DR: Insulin-like growth factor-I and its binding protein: In Endocrinology, DeGroot LJ, Jameson JL (eds) Elsevier pp 643-674, 2005.

45. Clemmons DR: Clinical utility of measurements of insulin-like growth factor I. Nat Clin Pract Endocrinol Metab 2:436-46, 2006.

46. Clemmons DR: Involvement of insulin-like growth factor-I in the control of glucose homeostasis. Curr Opin Pharmacol 6:620-5, 2006.

47. Clemmons DR: Value of insulin-like growth factor system markers in the assessment of growth hormone status. Endocrinol Metab Clin North Am 36:109-29, 2007.

48. Clemmons DR: IGF-I assays: current assay methodologies and their limitations. Pituitary 10:121-128, 2007.

49. Clemmons DR: Long-acting forms of growth hormone-releasing hormone and growth hormone:effects in normal volunteers and adults with growth hormone deficiency. Horm Res 5:178-81, 2007.

50. Clemmons DR, Maile LA, Ling Y, Yarber J, Busby WH. Role of the integrin alphaVbeta3 in mediating increased smooth muscle cells responsiveness to IGF-I in response to hyperglycemic stress. Growth Horm IGF Res 17:265-270, 2007.

51. Clemmons DR. Modifying IGF-I activity: an approach to treat endocrine atherosclerosis and cancer disorders. Nat Rev Drug Discov 6:821-833, 2007.

52. Clemmons DR. Pituitary Disease, Netter Textbook of Medicine, Runge M, Greganti MA (eds), 2nd Edition, AB Sanders, Philadelphia p416-422, 2008.

53. Giustina A, Barkan A, Chanson P, Grossman A, Hoffman A, Ghigo E, Casanueva F, Colao A, Lamberts S, Sheppard M, Melmed S. Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults. J Endocrinol Invest 31:820-38, 2008

54. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94:1509-17, 2009

36 55. Clemmons DR. Role of IGF-I in skeletal muscle mass maintenance. Trends Endocrinol Metab. 20:349-56, 2009

56. Frystyk J, Freda P, Clemmons DR. The current status of IGF-I assays – A 2009 update. Growth Horm IGF Res 20:8-18, 2010.

57. Clemmons DR. The diagnosis and treatment of growth hormone deficiency in adults. Curr Opin Endocrinol Diabetes Obes 17:377-83, 2010.

58. Clemmons DR. Insulin-like growth factor I and its binding proteins. In Endocrinology, DeGroot and J Jameson JL eds, Elsevier pp454-478, 2010.

59. Yakar S, Courtland HW, Clemmons DR. IGF-I and bone: New discoveries from mouse models. J Bone Miner Res 25:2267-2276, 2010.

60. Clemmons DR. Clinical laboratory indices in the treatment of acromegaly. Clin Chim Acta 412:403-409, 2010.

61. Clemmons DR, Maile LA, Xi G, Shen X, Radhakrishnan Y. IGF-I signaling in response to hyperglycemia and the development of diabetic complications. Curr Diabetes Rev 7:235- 244, 2011.

62. Clemmons DR. Approach to the patient with Endocrine Disease. Cecil’s Textbook of Medicine; Goldman L and Schaffer AI eds Elsevier, Philidelphia, Pa pp1420-1423.

63. Clemmons DR. Approach to the patient with Endocrine Disease. Cecil’s Textbook of Medicine; Goldman L and Schaffer AI eds Elsevier, Philidelphia, Pa pp1420-1423

Abstracts and Presentations

1. Hintz RL, Clemmons DR, Van Wyk JJ; Growth hormone induced somatomedin-like activity from liver.Ped. Res. 6:88, 1972.

2. Underwood LE, Hintz RL, Clemmons DR, Voina SJ, Turkington RW, Van Wyk JJ: Prolactin and TSH responses to thyroptropin releasing hormone and chlorpromazine in hypopituitary dwarfs: An attempt to assess hypothalmic function. Presented to the Annual Meeting of the Society for Pediatric Research, Washington, D.C., May 1972.

3. Van Wyk JJ, Underwood LE, Hintz RL, Clemmons DR, Voina SJ, Weaver RP: The Somatomedins: A family of insulin-like hormones under growth hormone control. Presented at the Laurentian Hormone Conference, Mon Tramblant, Canada, August 1973.

4. Hintz RL, Underwood LE, Clemmons DR, Voina SJ, Marshall RN, Van Wyk JJ: Separate receptors for insulins and somatomedin in skeletal and nonskeletal tissues. Presented to the 56th Meeting of the Endocrine Society, Atlanta, GA, June 1974.

5. Van Wyk JJ, Underwood LE, Hintz RL, Clemmons DR, Marshall RN: Explorations of the insulin-like and growth promoting properties of somatomedin by membrane receptor assay. Presented to the Nobel Symposium on the Somatomedians, Stockholm, Sweden, September 1974.

37 6. Clemmons DR, Van Wyk JJ, Ridgway EC, Klimana B, Kjelberg RN, Underwood LE: The diagnosis of acromegaly with a single measurement of somatomedin-C by radioimmunoassay. Presented to the Association of American Physicians, Washington, DC, May 4, 1979.

7. Clemmons DR, Van Wyk JJ, Pledger WJ: Sequential addition of platelet factor and plasma to fibroblasts stimulates somatomedin-C binding early in the cell cycle. Presented to the Endocrine Society, Anaheim, California, June 14, 1979.

8. Underwood LE, Copeland KC, Clemmons DR, Chatelain PG, Blethen SL, Van Wyk JJ: Radioimmunoassay of somatomedin-C: Clinical applications. Presented to the 10th Congress of the International Diabetes Federation, Vienna, Austria, September 9-15, 1979.

9. Van Wyk JJ, Underwood LE, Svoboda ME, Clemmons DR, Klapper DG, Fellow RE, Rothstein H: Somatomedin-C: Chemistry and biology. Presented to International Symposium on Growth Hormone and Related Peptides, Milan, Italy, September 1979.

10. Clemmons DR, Van Wyk JJ: Hormonal control of human fibroblast proliferation. Presented to the Conference on Endocrine Aspects of Aging, Bethesda, MD, October 1979.

11. D'Ercole AJ, Underwood LE, Clemmons DR, Van Wyk JJ: Somatomedin-C: Molecular structure, biological actions, and in role in post-natal and fetal growth. Presented to the VI International Congress of Endocrinology. Melbourne, Australia, February 1980.

12. Clemmons DR: The control of human fibroblast replication by peptide growth factors. Presented to the 5th Annual Symposium of the Cancer Research Center on the Regulation of Cell Proliferation, Chapel Hill, NC, March 1980.

13. Clemmons DR, Underwood LE, Van Wyk JJ: Human growth hormone stimulates fibroblast replication through somatomedin production in vitro. Meeting of the American Society of Clinical Investigation, Washington, DC, May 10-12, 1980.

14. Van Wyk JJ, Underwood LE, D'Ercole AJ, Clemmons DR, Pledger WJ, Wharton WE, Leof EB: Role of somatomedin in cellular proliferation. Presented to the Nobel Symposium on the Biology of Growth, Stockholm, Sweden, August 28-30, 1980.

15. Clemmons DR: Low molecular weight mitogen of platelet origin stimulates endothelial replication. American Heart Association, Dallas, Texas, November 12-14, 1981.

16. Isley WL, Underwood LE, Clemmons DR: Nutritional regulation of serum somatomedin-C concentrations in humans. Presented to the Southern Society of Clinical Investigation, New Orleans LA, January 14-16, 1982.

17. Underwood LE, Clemmons DR, Chatelain PG, Copeland KC, Van Wyk JJ: Plasma immunoreactive somatomedin-C/IGF-I in the evaluation of short stature. Presented to the Symposium on Insulin-like Growth Factors/Somatomedin-C, Nairobi, Kenya, November 13-15, 1982.

18. Underwood LE, Smith EP, Van Wyk, JJ, Clemmons DR, D'Ercole AJ, Pandian MR, Preece MA, Moore WV: Somatomedin-C/insulin-like growth factor I: Regulation and clinical applications. Symposium on Human Growth Hormone, Baltimore, MC, November 1983.

19. Clemmons DR, Seek MM, Underwood LE: Use of somatomedin-C as an index of the efficiency of nutritional therapy. American Federation for Clinical Research, Washington, DC, May 4-6, 1984.

20. Underwood LE, Van Wyk JJ, D'Ercole AJ, Clemmons DR, Svoboda ME: Insulin-like growth factors/somatomedins: Physiology and GH dependency. Presented to the International Congress of Endocrinology, Quebec City, Canada, July 1-7, 1984.

21. Clemmons DR, Underwood LE: Use of plasma somatomedin-C measurements to monitor the response to nutritional repletion. Presented to the Ross Conference on Pediatrics Research, Scottsdale, AZ, November 8-11, 1984.

22. Clemmons DR: Control of smooth muscle cell replication by secretion of a somatomedin- like peptide. American Society for Clinical Investigation, May 3-5, 1985.

23. Clemmons DR, Elgin RG, Han VKM, Casella SJ, Van Wyk JJ: Human fibroblasts secretes a factor that alters somatomedin-C binding to its cell surface receptor. Endocrine Society, Baltimore, MD, June 14-16, 1985.

24. Clemmons DR, Elgin RG: Somatomedin-C binding to cultured human fibroblasts is dependent upon donor age and culture density. Endocrine Society, Baltimore, MD, June 14-16, 1985.

25. Vender RL, Clemmons DR, Kwock L, Friedman M: Hypoxic exposure in-vitro to pulmonary endothelial cells cause release of a pulmonary vascular smooth muscle cell mitogen(s). Presented to the American Thoracic Society, June 1985.

26. Vender RL, Clemmons DR, Kwock L, Friedman M: Pulmonary artery smooth muscle cells (SMC) produce SMC growth promoting factor(s). Presented to the American Heart Association, July 1985.

27. Clemmons DR, Friedman M, Vender RL: Pulmonary endothelial cells produce a vascular smooth-muscle cell mitogen(s) in response to hypoxia. Presented to the Royal Society of Pulmonary Biology, Cambridge, England, 1985.

28. Lowry SF, Legaspi A, Jeevanandam M, Horowitz GD, Underwood LE, Clemmons DR, Albert JD, Breenan MF: Influence of non-protein caloric source on whole-body protein kinetics and somatomedin-C levels during unstressed intravenous feeding. Presented to the European Society of Parenteral and Enteral Nutrition 7th Congress, Munich, Germany, September 9-11, 1985.

29. Clemmons DR, Dehoff M, Drop LS: Biosynthesis of a 35K somatomedin-C binding protein by cultured fibroblasts. Presented to the American Society of Biological Chemistry, Washington DC, June 11, 1986.

30. Dehoff M, Elgin RG, Collier RJ, Clemmons DR: Insulin-like growth factor receptor subtypes are regulated during bovine lactation. Presented to the Endocrine Society, Anaheim, CA, June 25-27, 1986.

31. Han VKM, Elgin RG, D'Ercole AJ, Clemmons DR: Modulation of 125I-somatomedin- C/insulin-like growth factor I binding to cultured human fibroblast monolayers by a

39 35000d binding protein that associates with the cell surface. Presented to the Endocrine Society, Anaheim, CA, June 25-27, 1986.

32. McCusker RH, Campion DA, Clemmons DR: Ontogeny of an insulin like growth factor binding protein in porcine fetal plasma. Presented to the American Society of Animal Science, Manhattan, Kansas, July 31, 1986.

33. Snyder DK, Clemmons DR, Underwood LE: Use of growth hormone to promote lipolysis and conserve lean body mass. Presented to the Southern Society of Clinical Investigation, New Orleans, LA, January 39, 1987.

34. Brown AL, Chariotti L, Clemmons DR, Fronzio R, Bruni CB, Rechler MM: Regulation of rat insulin-like growth factor II (rIGF-II) gene expression by polyadenylation at different sites. Presented to the American Society of Clinical Investigation. San Diego, CA, May 4, 1987.

35. Clemmons DR, Elgin RG, Busby WH: An insulin-like growth factor binding protein enhances the biological response to somatomedin-C. Presented to the American Federation for Clinical Research, San Diego, CA, May 4, 1987.

36. Clemmons DR, Elgin RG, Busby WH, McCusker RH: Insulin like growth factor binding proteins are biologically active and modulate the cellular growth response to somatomedin-C. Presented to the Endocrine Society. Indianapolis, IN, June 8, 1987.

37. McCusker RH, Clemmons DR: The regulation of insulin-like growth factor binding protein secretion by muscle cells. Presented to the Endocrine Society. Indianapolis, IN, June 9, 1987.

38. Clemmons DR, Brewer M, Squires C, Busby WH, Thompson RG: Cloning and c-DNA sequence determination of an IGF binding protein that is present in human amniotic fluid. Presented to the American Society for Clinical Investigation. Washington, DC, May 1, 1988.

39. Friedman M, Clemmons DR: Hypoxia stimulates the de novo synthesis and release of a pulmonary vascular smooth muscle cell (PVSMC) mitogen in cultured pulmonary endothelial cells (PEC). Presented to the American Thoracic Society, May 1988.

40. Snyder DK, Clemmons DR, Underwood LE: Growth hormone may mediate the nitrogen sparing effect of carbohydrate in diet restricted subjects. Presented to the American Federation for Clinical Research, Washington, DC, May 1, 1988.

41. Bauman G, Shaw MA, Merimee TJ, Clemmons DR: Growth hormone binding protein in human plasma: Down regulation by prolonged fasting in lean but not obese subjects. Presented to the American Federation for Clinical Research, May 1, 1988.

42. Camacho-Hubner C, McCusker RH, Clemmons DR: Insulin-like growth factor binding protein secretion by human tumor cells is hormonally regulated. Presented to the Endocrine Society. New Orleans, LA, June 8, 1988.

43. McCusker RH, Camacho-Hubner C, Clemmons DR: Analysis of the forms of insulin-like growth factor binding proteins secreted by muscle cells. Presented to the Endocrine Society. New Orleans, LA, June 8, 1988.

44. McCusker RH, Campion DR, Clemmons DR: The insulin-like growth factor binding proteins of porcine sera: Endocrine and nutritional regulation. Presented to the American Society of Animal Science. Rutgers University, July 19-22, 1988.

45. Thrailkill K, Clemmons DR, Handwerger S: Differential regulation of insulin-like growth factor binding proteins in decidual cells. Presented to the American Society for Clinical Investigation. Washington, DC, May l, 1989.

46. Camacho-Hubner C, Gardner LW, McCusker RH, Clemmons DR: The 30000 Mr insulin- like growth factor binding protein in the predominant form in the extracellular matrix. Presented to the Endocrine Society. Seattle, WA, June 23, 1989.

47. McCusker RH, Camacho-Hubner C, Clemmons DR: The role of insulin-like growth factor binding protein controlling IGF binding to the cell surface. Presented to the Endocrine Society. Seattle, WA, June 23, 1989.

48. McCusker RH, Camacho-Hubner C, Clemmons DR: Control of IGFBP secretion by muscle cells. Presented to the Mid Atlantic Diabetic Association. Bethesda, MD. September 18, 1989.

49. Cohick WS, McCusker RH, Clemmons DR: Insulin-like growth factor binding proteins (IGFBP's) modulate IGF-I binding and cell growth responses of their MDBK cells. Presented to the Endocrine Society, Atlanta, GA, June 21, 1990.

50. McCusker RH, Busby WH, Dehoff M, Camacho-Hubner C, Clemmons DR: Insulin-like growth factors (IGF) binding to cell monolayers is modulated by the addition of binding proteins (IGFBP's). Presented to the Endocrine Society, Atlanta, GA, June 22, 1990.

51. Cohick WS, Busby WH, Clemmons DR, Bauman DE: Insulin-like growth factor binding proteins (IGFBP) in serum of lactating cows treated with recombinant N-methionlyl bovine somatotropin (BST). Presented to the Annual Meeting of the American Society of Animal Science, Ames Iowa, July, 1990.

52. McCusker RH, Cohick WS, Busby WH, Clemmons DR: Control of insulin-like growth factor binding protein (IGFBP-2) levels in porcine serum by growth hormone status. Presented to the Annual Meeting of the American Society of Animal Science, Ames Iowa, July, 1990.

53. Jones JI, Busby WH, Clemmons DR: Phosphorylation of IGFBP-1. Presented to the Mid Atlantic Diabetic Symposium, Bethesda, MD, September 17, 1990.

54. Jones JI, Clemmons DR: The bioactivity of an insulin-like growth factor binding protein is modulated by serine phosphorylation. Presented to the Southern Society for Clinical Investigation, New Orleans, LA, January, 1991.

55. Young SCJ, Smith-Banks A, Clemmons DR: Effects of recombinant IGF-I and GH binding protein concentrations in calorically restricted humans. Presented to the 73rd Annual Meeting of the Endocrine Society, Washington, DC, June 19-22, 1991.

56. Jones JI, D'Ercole AJ, Camacho-Hubner C, Clemmons DR: Insulin-like growth factor binding protein-1 (IGFBP-1) phosphorylation in cell culture and in vivo: effects on affinity

41 for IGF-I. Presented to the 73rd Annual Meeting of the Endocrine Society, Washington, DC, June 19-22, 1991.

57. Camacho-Hubner C, McCusker RH, Clemmons, DR: Secretion of IGFBP's by tumor cells. Presented to the Mid Atlantic Diabetes Symposium, Bethesda, MD, September 21, 1991.

58. Jones JI, Gockerman A, Clemmons DR: Insulin-like growth factor binding protein-5 (IGFBP-5) binds to extracellular matrix and is phosphorylated. Presented to the 74th Annual Meeting of the Endocrine Society, San Antonio, TX, June 1992.

59. McCusker RH, Jones JI, Clemmons DR: Insulin-like growth factor (IGF)-binding protein-1 (IGFBP-1) is phosphorylated in porcine sera. Presented to the American Society of Animal Science & International Society of Applied Ethology, Pittsburgh, PA, August 8- 11, 1992.

60. Armstrong JD, Cohick WS, Harvey RW, Huff BG, Guidi PDS, Campbell RM, Campbell RM, HeimerEP, Clemmons DR, Whitacre MD: Effect of active immunization against growth hormone releasing factor (GRFi) on follicular growth, serum and follicular insulin-like growth facto I (IGF-I) and IGF binding proteins (IGFBP), and onset of puberty in heifers. Presented to the American Society of Animal Science & International Society of Applied Ethology. Pittsburgh, PA, August 8-11, 1992.

61. Camacho-Hubner C, McCusker RH, Clemmons DR: Control of IGFBP secretion in human glioblastoma cells. Presented to the 14th Meeting of the International Endocrine Society, Nice, France, August 28, 1992.

62. Young SCJ, Clemmons DR: Role of IGF-I in type II diabetes. Presented to the Mid Atlantic Diabetes Symposium, Bethesda, MD, September 26, 1992.

63. Jones JI, Gockerman A, Wright G, Clemmons DR: Stimulation of cell migration by IGF binding protein-1 is dependent on the Arg-Gly-Asp sequence and independent of IGF-I presented to the 75th Annual Meeting of the Endocrine Society, Las Vegas, NV, June 9, 1993.

64. Nam TJ, Busby WH, Clemmons DR: Characterization and purification of a serine protease that is secreted by human fibroblasts and cleaves IGF binding protein-5. Presented to the 75th Annual Meeting of the Endocrine Society, Las Vegas, NV, June 10, 1993.

65. Smith WJ, Underwood LE, Clemmons DR: Effects of nutrient restriction on IGF-I and IGF binding proteins in children. Presented to the Southern Society of Clinical Investigation, New Orleans, LA, Jan. 17, 1994.

66. Jones JI, Clemmons DR: RGD dependent binding of IGFBP-1 to cell surface integrins of fibroblasts and smooth muscle cells. Presented to the Third International Symposium on Insulin-Like Growth Factors, Sydney, Australia, February 6-11, 1994.

67. Chernausek SD, Busby WH, Clemmons DR: Localization of rat IGFBP-4 cleavage site. Presented to the Third International Symposium on Insulin-Like Growth Factors, Sydney, Australia, February 6-11, 1994.

42 68. Clemmons DR: Determinants of IGFBP-5 binding to extracellular matrix. Presented to the Third International Symposium on Insulin-Like Growth Factors, Sydney, Australia, February 6-11, 1994.

69. Camacho-Hubner C, Yateman ME, Wass T, Clemmons DR: Cytokine regulation of IGFBPs produced by human fibroblasts. Presented to the Third International Symposium on Insulin-Like Growth Factors, Sydney, Australia, February 6-11, 1994.

70. Camacho-Hubner C, Merchenthaler I, Cotterill A, Balasubramanyan A, Busby WH, Clemmons DR: Coexpression of IGF-II and IGFBP-2 by non-islet cell tumors. Presented to the Third International Symposium on Insulin-Like Growth Factors, Sydney, Australia, February 6-11, 1994.

71. Arai T, Arai A, Clemmons DR: Heparin, heparan sulfate and dermatan sulfate inhibit IGFBP-5 degradation in human fibroblasts. Presented to the 76th Annual Meeting of the Endocrine Society, Anaheim, CA, June 15-18, 1994, Abstract #391.

72. Arai T, Clemmons DR: Heparin heparan sulfate and dermatan sulfate inhibit formation of the IGF-I-IGFBP complex. Presented to the 76th Annual Meeting of the Endocrine Society, Anaheim, CA, June 15-18, 1994, Abstract #951.

73. Duan C, Clemmons DR: Transcription factor AP-2 regulates insulin like growth factor binding protein-5 (IGFBP-5) gene expression. Presented to the 77th Annual Meeting of the Endocrine Society, Washington, DC, June 13-17, 1995.

74. Zeigler TR, Smith RJ, Clemmons DR: Alterations in circulating IGF-I and IGFBPs in catabolic patients during parenteral feeding. Presented to the 77th Annual Meeting of the Endocrine Society, Washington, DC, June 14-17, 1995.

75. Nam TJ, Busby WH, Clemmons DR: The IGFBP-5 proteolytic activity secreted by human fibroblasts is a 95 kDa serine protease. Presented to the 77th Annual Meeting of the Endocrine Society, Washington, DC, June 14-17, 1995.

76. Arai T, Clarke J, Parker A, Busby WH, Clemmons DR: Identification of basic amino acids responsible for heparin induced decrease in binding affinity of IGFBP-5 for IGF-I. Presented to the 77th Annual Meeting of the Endocrine Society, Washington, DC, June 14-17, 1995.

77. Tamaraglio TA, Clemmons DR: The effect of glucose on insulin like growth factor binding protein-4 proteolysis. Presented to the 77th Annual Meeting of the Endocrine Society, Washington, DC, June 14-17, 1995.

78. Cohick WS, Gockerman A, Clemmons DR: The effects of PDGF the IGFs and serum deprivation on IGFBP-2 synthesis and degradation by vascular smooth muscle cells. Presented to the 77th Annual Meeting of the Endocrine Society, Washington, DC, June 14-17, 1995.

79. Moses AC, Morrow LA, O'Brien M, Young S, Clemmons DR: The effect of six weeks of subcutaneous IGF-I on glycemic control and on serum IGF and IGF binding proteins levels in type II diabetics. Presented to the 77th Annual Meeting of the Endocrine Society, Washington, DC, June 14-17, 1995.

43 80. Jones JI, Gockerman A, Clemmons DR: IGF stimulation of vascular smooth muscle cell migration. Contribution of the V3 integrin. Presented to the 77th Annual Meeting of the Endocrine Society, Washington, DC, June 14-17, 1995.

81. Duan C, Parker A, Clemmons DR: Regulation of insulin like growth factor binding protein-5 gene expression in vascular smooth muscle cells. Presented to the 10th International Congress in Endocrinology, San Francisco, CA, June 12-15, 1996.

82. Arai T, Nam TJ, Parker A, Busby WH, Clemmons DR: IGF-I and IGF-II binding to IGFBP-2 is required for its association with heparin in extracellular matrix. Presented to the 10th International Congress in Endocrinology, San Francisco, CA, June 12-15, 1996.

83. Parker A, Clarke J, Busby WH, Clemmons DR: Mutations of specific residues in IGFBP-5 reduce binding to extracellular matrix. Presented to the 10th International Congress in Endocrinology, San Francisco, CA, June 12-15, 1996.

84. Nam TJ, Busby WH, Clemmons DR: Plasminogen activator inhibitor-1 binds to insulin- like growth factor binding protein-5. Presented to the 10th International Congress in Endocrinology, San Francisco, CA, June 12-15, 1996.

85. Clemmons DR, Murphy MG, Plunkell LM, Polvino WM, He W, Wittreich J, Gertz, BJ: MK-677 an orally active growth hormone (GH) secretagogue reverses diet-induced catabolism. Presented to the 2nd International Meeting of the Growth Hormone Research Society, London, England, November 15-18, 1996.

86. Moore D, Clemmons DR, Sommer A, Adams S: Safety, pharmacokinetics and biologic effects of intravenous administration of Rh IGF-I/IGFBP-3 to healthy subjects. Presented to the 79th Annual Meeting of the Endocrine Society, Minneapolis, MN, June 11-14, 1997.

87. Imai Y, Busby WH, Garmong AJ, Clarke JB, Horvitz G, Rees C, Clemmons DR: Protease resistant IGFBP-5 inhibits actions of IGF-I on porcine smooth muscle cells. Presented to the 79th Annual Meeting of the Endocrine Society, Minneapolis, MN, June 11-14, 1997.

88. Zheng B, Duan C, Clemmons DR: Changing phenotype of smooth muscle cell alters synthesis of IGFBP-5. Presented to the 79th Annual Meeting of the Endocrine Society, Minneapolis, MN, June 11-14, 1997.

89. Zheng B, Duan C, Clarke JB, Busby WH, Clemmons DR: Insulin-like growth factor binding protein-5 is a specific substrate for thrombin cleavage. Presented to the 79th Annual Meeting of the Endocrine Society, Minneapolis, MN, June 11-14, 1997.

90. Yoshizawa A, Busby WH, Clarke JB, Clemmons DR: Androgen-IGF-I interact to control IGFBP production in androgen responsive foreskin fibroblasts. Presented to the 79th Annual Meeting of the Endocrine Society, Minneapolis, MN, June 11-14, 1997.

91. Zheng B, Clemmons DR: Blocking V3 integrin occupancy results in decreased tyrosine phosphorylation of IRS-1 in response to IGF-I. Presented to the 80th Annual Meeting of the Endocrine Society, New Orleans, LA, June 25, 1998.

92. Nam TJ, Horvitz GD, Rees C, Clemmons DR: Extracellular matrix proteins thrombospondin and osteopontin bind to the V3 integrin also specifically bind to

44 IGFBP-5. Presented to the 80th Annual Meeting of the Endocrine Society, New Orleans, LA, June 24, 1998.

93. Yoshizawa A, Clemmons DR: IGF binding protein-5 synthesis is regulated by testosterone through gene transcriptional mechanisms in androgen responsive human fibroblasts. Presented to the 80th Annual Meeting of the Endocrine Society, New Orleans, LA, June 24, 1998.

94. Barkan A, Dimati E, Beser GM, Trainer P, Vanderlely AJ, Lamberts S, Benet V, Melmed S, Clemmons DR, Rose R, Vance ML, Thomas M: Treatment of acromegaly with B2036 PEG, a growth hormone receptor antagonist. Presented to the 81st Annual Meeting of the Endocrine Society, San Diego, CA, June 13, 1999.

95. Clemmons DR, Moses AM, Sommer A, McKay MC, Rosen D, Ruckle J: The combination of IGF-I and IGFBP-3 enhances insulin sensitivity in type I diabetes mellitus. Presented to the 81st Annual Meeting of the Endocrine Society, San Diego, CA, June 14, 1999.

96. Rose DR, Clemmons DR: Growth hormone receptor antagonist induces improvement in insulin sensitivity in acromegaly. Presented to the 81st Annual Meeting of the Endocrine Society, San Diego, CA, June 12, 1999.

97. Imai Y, Clemmons DR: Relative importance of PI 3-kinase and MAPK pathways in stimulation of vascular smooth muscle cell migration by IGF-I. Presented to the 81st Annual Meeting of the Endocrine Society, San Diego, CA, June 12, 1999.

98. Maile LA, Clarke JB, Clemmons DR: Mutagenesis of specific amino acids in the subdomain structure of the 3 integrin alters IGF-I actions. Presented to the 6th International Symposium on Insulin-like Growth Factors, Brighton, UK, November 2, 1999.

99. Imai Y, Clemmons DR: Mutagenesis of specific amino acids in the N-terminus of IGFBP-3 and IGFBP-5 attenuates IGF-I binding and alters IGF-I actions. Presented to the 6th International Symposium on Insulin-like Growth Factors, Brighton, UK, November 2, 1999.

100. Maile LA, Imai Y, Clarke JB, Clemmons DR: A role for integrin associated protein (IAP) in IGF-I stimulated migration of vascular smooth muscle cells. Presented to the 82nd annual meeting of the Endocrine Society, Toronto, CA, June 23, 2000.

101. Maile LA, Clemmons DR: A role for SHP-2 phosphatase and SHP sulfate 1 (SHPS-1) in the V3 integrin receptor mediated regulation of IGF-I receptor phosphorylation. Presented to the 82nd annual meeting of the Endocrine Society, Toronto, CA, June 23, 2000.

102. Sakai K, D’Ercole AJ, Murphy L, Clemmons DR: Physiologic differences in phosphorylation of insulin-like growth factor binding protein-1 in IGFBP-1 transgenic mice. Presented to the 82nd annual meeting of the Endocrine Society, Toronto, CA, June 21, 2000.

103. Sakai K, Busby WH, Clemmons DR: Tissue transglutaminase facilitates the polymerization of insulin-like growth factor binding protein-1 (IGFBP-1), and a polymerization resistant IGFBP-1 mutant form inhibits insulin-like growth factor-I (IGF-

45 I) action in porcine smooth muscle cells in vitro. Presented to the 82nd annual meeting of the Endocrine Society, Toronto, CA, June 22, 2000.

104. Rose R, Clemmons DR: Growth hormone receptor antagonist improves insulin resistance in acromegaly. Presented to the Fourth International Meeting of the Growth Hormone Research Society. Goteborg, Sweden, September 8, 2000.

105. Busby WH, Nam TJ, Moralez A, Smith C, Jennings M, Clemmons DR: Complement components C1r and C1s account for IGFBP-5 protease activity secreted by fibroblasts and smooth muscle cells in culture. Presented to the Fourth International Meeting of the Growth Hormone Research Society. Goteborg, Sweden, September 8, 2000.

106. Clemmons DR, Busby WH, Garmong A, Schultz D,R, Howell DS, Karr R: Inhibition of IGFBP-5 proteolysis in cartilage results in reduced joint destruction in dog osteoarthritis. Presented to the Fourth International Meeting of the Growth Hormone Research Society. Goteborg, Sweden, September 7, 2000.

107. Maile LA, Clemmons DR: Molecular mechanisms by which V3 antagonists inhibit IGF- I signaling. Presented to the Fourth International Meeting of the Growth Hormone Research Society. Goteborg, Sweden, September 9, 2000.

108. Nam TJ, Clemmons DR: Determination of the regions of IGFBP-5 that bind to vitronectin and the effects of vitronectin/IGFBP-5 interaction on cell responsiveness to IGF-I. Presented to the Fifth International Symposium on IGF Binding Proteins. Terrigal, Australia, October 29, 2000.

109. Ishida A, Clemmons DR: Amino acid sequences within thrombospondin and osteopontin that mediate binding to insulin-like growth factor binding protein-5: Effects of thrombospondin on IGF-I actions. Presented to the Fifth International Symposium on IGF Binding Proteins. Terrigal, Australia, October 30, 2000.

110. Clemmons DR, Moses A, Jacobson W, Rogol A, Summer A, Allan G: IGF-I/IGFBP-3 by injection or infusion to type 2 diabetics increases free IGF-I and reduces insulin requirements. Presented to the 83rd Annual Meeting of the Endocrine Society. Denver, Co, June 20, 2001

111. Maile L, Clemmons DR: IGF-I regulates the cellular localization of integrin activating protein (IAP). Presented to 83rd Annual Meeting of the Endocrine Society. Denver, Co, June 22, 2001

112. Grinspoon S, Thomas E, Miller K, Bodio K, Mulcahey M, Herzog D, Clemmons DR, Klibanski A: Effect of rh IGF-I and estrogen administration on IGF-I, IGFBP-2 and IGFBP- 3 in anorexia nervosa. Presented to 83rd Annual Meeting of the Endocrine Society. Denver, Co, June 22, 2001.

113. Maile L, Clemmons DR: Ligand occupancy of IAP alters SHPS-1 phosphorylation in response to IGF-I stimulation. Presented to 83rd Annual Meeting of the Endocrine Society. Denver, Co, June 20, 2001.

114. Sakai K, Lowman H, Clemmons DR: A synthetic peptide that inhibits insulin-like growth factor-I (IGF-I) binding to IGF binding protein-1 enhances insulin sensitivity in human

46 hepatoma cell cultures. Presented to the 83rd Annual Meeting of the Endocrine Society. Denver, Co, June 21, 2001

115. Nam TJ, Moralez A, Clemmons DR: Vitronectin binding to insulin-like growth factor binding protein-5 (IGFBP-5) alters IGFBP-5 modulation of IGF-I actions. Presented to the 83rd Annual Meeting of the Endocrine Society. Denver, Co, June 21, 2001.

116. Perks CM, Clarke JB, McCaig C, Clemmons DR, Holly JM: Non IGF binding mutants of IGFBP-3 and 5 retain their IGF-I independent effects on apoptosis in HS 578T human breast cancer cells. Presented to the 83rd Annual Meeting of the Endocrine Society. Denver, Co, June 21, 2001.

117. Blum W, Attanasio A, Crowe B, Selender K, Clemmons DR, Ho K, Strasburger C, Sizemenko P, Cutler G: Long term IGF-I and IGFBP-3 response to GH replacement in adult patients with childhood (Co) and adult (AO) onset GH deficiency (GHD). Presented to the 83rd Annual Meeting of the Endocrine Society. Denver, Co. June 22, 2001.

118. Ling Y, Maile LA, Clemmons DR. Regulation of IGF-IR tyrosine phosphorylation by th dephosphorylation of integrin B3. Presented to the 84 Annual Meeting of the Endocrine Society, San Francisco, Ca, June 21, 2002.

119. Sakai K, Clemmons DR. Glucosamine induced insulin resistance induces insulin-like growth factor-I (IGF-I) and insulin resistance in Hep G2 cell cultures: Biological significance of IGF-I/insulin hybrid receptors. Presented to the 84th Annual Meeting of the Endocrine Society. San Francisco, Ca. June 19, 2002.

120. O’Connell T, Clemmons DR. IGF-I/IGFBP-3 combination improves insulin resistance by GH dependent and independent mechanisms. Presented to the 84th Annual meeting of the Endocrine Society. San Francisco, Ca. June 19, 2002.

121. Perks CM, Clarke JB, McCrary C, Clemmons DR. Intrinsic effects of IGFBP-5 on cell diameter in human breast cancer cells. Presented to the 84th Annual Meeting of the Endocrine Society. San Francisco, Ca. June 19, 2002.

122. Maile LA, Clemmons DR. The IGF-I receptor associates with integrin associated protein (IAP) . Presented to the 84th Annual Meeting of the Endocrine Society, San Francisco, Ca. June 20, 2002.

123. Clemmons DR, Sleevi M, Busby WH. Recombinant Human IGFBP-3 is preferentially degraded in humans in vivo and administration of RH IGFBP-3 to diabetics results in a decrease in the concentration of glycosylated IGFBP-3 in serum. Presented to the 84th Annual Meeting of the Endocrine Society, San Francisco, Ca. June 20, 2002.

124. Ling Y, Maile LA, Clemmons DR. Role of the cytoplasmic domain of integrin 3 in regulating IGF-I signaling. Presented to the 1st Joint Symposium of GRS and IGF Societies, Boston Mass, October 6, 2002.

125. Kwon MJ, Maile LA, Clemmons DR. The V3 disintegrin echistatin acts at multiple points to inhibit IGF-I induced activation of the PI-3 kinase pathway in vascular smooth muscle cells. Presented to the 1st Joint Symposium of the GRS And IGF Societies, Boston Mass, October 6, 2002

126. Maile LA, Clemmons DR. Regulation of IGF-I receptor phosphorylation by integrin associated protein and SHPS-1. Presented to the 1st Joint Symposium of the GSH and IGF Societies, Boston Mass, October 6, 2002.

127. Maile LA, Clemmons DR. SHP-2 recruitment to the IGF-I receptor following inhibition of normal SHPS-1 transfer. Presented to the 1st Joint Symposium of the GRS and IGF Societies, Boston Mass, October 6, 2002.

128. Clemmons, DR, Barkan AL, Monson JP, Drake WM, Friend KE, Burman P. Pegvisomant improves glucose homeostasis in patients with acromegaly previously treated with Octreotide LAR. Presented to the 85th Annual Meeting of the Endocrine Society Philadelphia, PA, June 20, 2003.

129. Clemmons DR. Safety assessment and metabolic effects of TH9507, a growth hormone releasing factor analogue (GRF) in patients with type 2 diabetes mellitus. Presented to the 85th Annual Meeting of the Endocrine Society, Philadelphia, PA, June 20, 2003.

130. Ling Y, Clemmons DR. Recruitment of tyrosine phosphatase SHP-2 to the Src homology 2 domains- containing tyrosine phosphatase substrate-1, SHPS-1 and SHPS-1 dephosphorylation are required for activating SHC and sustained MAPK in response to IGF-I in nontransfected smooth muscle cells. Presented to the 85th Annual Meeting of the Endocrine Society , Philadelphia, PA, June 19, 2003.

131. Kwon MJ, Maile LA, Clarke JB, Clemmons DR. Regulation of insulin-like growth factor-I stimulated p85/p110 PI3 kinase complex activation by tyrosine phosphatase SHP-2. Presented to the 85th Annual Meeting of the Endocrine Society, Philadelphia, PA, June 21, 2003.

132. Maile LA, Clemmons DR. The integrin associated protein binding domain of thrombospondin-1 enhances IGF-I signaling in vascular smooth muscle cells. Presented to the 85th Annual Meeting of the Endocrine Society, Philadelphia, PA, June 21, 2003.

133. Kwon MI, Clarke JB, Maile LA, Clemmons DR. Role of SHP-2 in IGF-I stimulated PI3- Kinase Activation of Vascular Smooth Muscle Cells. Presented to the 86th Annual Meeting of the Endocrine Society, New Orleans, LA, June 16-19 2004.

134. Ling Y, Maile LA, Tenenbaum S, Clemmons DR. Role of Dok1 in mediating the association of the protein tyrosine phosphatase SHP-2 and the αVβ3 integrin in cultured vascular smooth muscle cells. Presented to the 86th Annual Meeting of the Endocrine Society, New Orleans, LA, June 16-19 2004.

135. Tenenbaum S, Maile LA, Clemmons DR. A role for p130Cas in the regulation of IGF its regulation of SHP-2 recruitment and transfer. Presented to the 86th Annual Meeting of the Endocrine Society, New Orleans, LA, June 16-19, 2004.

136. Sergent T, Busby WH, Maile LA, Clemmons DR. The heparin binding domain of vitronectin signaling through activation of αVβ3 in RGD independent. Presented to the 86th Annual Meeting of the Endocrine Society, New Orleans, LA, June 16-19, 2004.

137. Maile LA, Clemmons DR. Activation of calpain in response to IGF-I stimulation for release of SHP-2 from αv3 integrin and regulates the transfer of SHP-2 to the IGF-I

48 receptor. Presented to the 86th Annual Meeting of the Endocrine Society, New Orleans, LA, June 16-19, 2004.

138. Maile LA, Ling Y, Clemmons DR: Ligand occupancy of the αVβ3 integrin regulates its clustering with transmembrane protein IAP and SHPS-1 which is necessary for Shc phosphorylation and MAP kinase activation in response to IGF-I. Presented to the 87th Annual meeting of the Endocrine Society San Diego, CA June 3-7, 2005.

139. Jimenez C, Clemmons DR, Drake WM, Hutson KD, Thorner MO, Trainer PJ, Gagel RF: Long-term follow up of pituitary tumor volume in patients with acromegaly treated with Pegvisomant. Presented to the 87th Annual meeting of the Endocrine Society San Diego, CA June 3-7, 2005.

140. Pennisi P, Garilova O, setser-Portas J, Santo Pietro S, Clemmons Dr, Yakan S, LeRoith D: Effect of insulin-like growth factor-I treatment on glucose metabolism in a transgenic mouse model of type 2 diabetes. Presented to the 87th Annual meeting of the Endocrine Society San Diego, CA June 3-7, 2005.

141. Ling Y, Lieskovsk J, Maile LA, Badley-Clark J, Clemmons Dr: Role of SHPS-1 in regulation of insulin-like growth factor (IGF-I) stimulated Shc and MAP kinase activation in vascular smooth muscle cells. Presented the 87th Annual meeting of the Endocrine Society San Diego, CA June 3-7, 2005.

142. Lieskovska J, Badley-Clarke, J, Clemmons DR: The heparin binding domain of HB-EGF positively modulates IGF-I dependent MAPK activation in psmc. Presented to the 87th Annual meeting of the Endocrine Society San Diego, CA June 3-7, 2005.

143. Maile LA, Capps B, Clemmons DR: Differential regulation of IGF-I receptor modulated signaling in cells cultured in high and low glucose conditions. Presented the 87th Annual meeting of the Endocrine Society San Diego, CA June 3-7, 2005.

144. Sipos JA, Clemmons DR, Busby WH, Nichols T: A protease resistant form of insulin-like growth factor binding protein-4 reduces atherosclerotic lesion size in hyperlipidemic pigs. Presented to the 87th Annual meeting of the Endocrine Society San Diego, CA June 3-7, 2005.

145. Molitch ME, Merriman G, Vance ML, Clemmons Dr: Evaluation and treatment of growth hormone deficiency. Endocrine Society Clinical Practice Guidelines. Presented to the 88th Annual Meeting of the Endocrine Society, Boston Mass, June 24, 2006.

145. Maile LA, Capps B, Clemmons DR: Glucose regulated changes in αVβ3 ligand occupancy regulate IGF-I signaling in vascular smooth muscle cells. Presented to the 88th Annual Meeting of the Endocrine Society, Boston, Mass June 26, 2006.

146. Yoo SE, Capps BE, Maile LA, Clemmons DR: Hyperglycemia is associated with changes in the IGF-I signaling pathway that enhance the vascular cell growth response in diabetic mice. Presented to the 88th Annual Meeting of the Endocrine Society, Boston Mass, June 26, 2006.

147. Maile LA, Capps BE, Clemmons DR: Glucose concentrations regulate the responsiveness of smooth muscle cells to IGF-I. Presented to the 88th Annual Meeting of the Endocrine Society, Boston Mass, June 26, 2006.

148. DeMambro VE, Clemmons DR, Ackert-Bicknell CL, Beamer WG, Khosla S, Wood T, Pintar J, Bouxsein ML, Rosen CJ. IGFBP-2 Null mice have abnormal peak bone acquisition. Presented to the 88th Annual Meeting of the Endocrine Society, Boston Mass, June 26, 2006.

149. Sharpless, JL, Clemmons DR. Growth hormone receptor blockade in polycystic ovary syndrome (PCOS). Presented to the 88th Annual Meeting of the Endocrine Society, Boston Mass, June 26, 2006.

150. Xi G, Clemmons DR: IGF-I and H2O2 Differentially stimulate p66Shc Ser 36, phosphorylation in pSMC cultures in high and normal glucose. Presented to the 88th Annual Meeting of the Endocrine Society, Boston Mass, June 26, 2006.

151. Radhakrishnan Y, Maile LA, Ling Y, Clemmons DR. IGF-I induced Shc-PDK1-AKT regulation in vascular smooth muscle cell proliferation. Presented to the 89th Annual Meeting of the Endocrine Society, Toronto Canada June 1-4, 2007.

152. Veluvlou V, Capps BE, Maile LA, Clemmons DR. A high throughput screening assay to test for compounds to inhibit IGF-I signaling in vascular smooth muscle cells in hyperglycemic conditions. Presented to the 89th Annual Meeting of the Endocrine Society, Toronto, Canada, June 1-4, 2007.

153. Xi G, Yoo SE, Clemmons DR. Optimization of signal transduction and IGF-I stimulated proliferation in an SMC by transfection of human β3 integrin subunit. Presented to the 89th Annual Meeting of the Endocrine Society, Toronto Canada, June 1-4, 2007.

154. Xi G, Clarke JB, Clemmons DR. p66Shc negatively regulates IGF-I signal transduction as well as IGF-I stimulated proliferation and progression of porcine smooth muscle cells (pSMC). Presented to the 89th Annual Meeting of The Endocrine Society, Toronto Canada, June 1-4, 2007.

155. Maile LA, Allen LB, Clemmons DR. Regulation of IGF-I signaling in smooth muscle cells by glucose-oxidized low density lipoprotein binding to CD36. Presented to the 89th Annual Meeting for The Endocrine Society. Toronto, Canada, June 1-4, 2007.

156. DeMambro VE, Clemmons D, Beamer WG, Bouxsein ML, Canalis E, Rosen CJ. Serum IGFBP-2 (IGF binding protein-2) is a marker of bone turnover: In vivo evidence from the IGFBP-2 null male mouse. Presented to American Society Bone and Mineral Res, Honolulu Hi, Sept 19, 2007.

157. Woodmansee SW, Hartman ML, Clemmons DR, Zagar AJ, Lamberts SWJ. Measurement of fasting hyperglycemia in growth hormone (GH)-deficient patients receiving GH replacement compared to untreated patients: Data from the Hypopituitary Control and Complications Study (HypoCCS). Presented to the 90th Annual Meeting of the Endocrine Society, San Francisco CA, June 15, 2008.

158. Shen X, Clemmons D. The novel role of SHPS-1 in insulin-like growth factor dependent cellular responses: Protein synthesis, protein aggregation and cell death in vascular smooth muscle cells (VSMCs). Presented to the 90th Annual Meeting of the Endocrine Society, San Francisco CA, June 16, 2008

50 159. Ning J, Clemmons DR. Role of AMP-activated protein kinase activation in regulation of IGF-I stimulated cell proliferation and protein synthesis. Presented to the 90th Annual Meeting of the Endocrine Society, San Francisco CA, June 16, 2008

160. Radhakrishnan Y, Rowland MA, Maile LA, Clemmons DR. IGF-I mediates mTOR and JNK dependent IRS-1 function in vascular smooth muscle cells. Presented to the 90th Annual Meeting of the Endocrine Society, San Francisco CA, June 16, 2008

161. Clemmons DR, Nichols T, Busby WH, Maile LA, Merricks, E. A monoclonal antibody that targets a novel site on the Beta3 subunit of the alphaVbeta3 integrin blocks lesion development in a porcine model of diabetic atherosclerosis. Presented to the Fourth International Congress of the GRS and IGF Society, Genoa Italy, Sept 16, 2008.

162. Demambro V, Rosen C, Clemmons DR. IGFBP-2 null mice develop obesity and insulin resistance with aging. Presented to the Fourth International Congress of the GRS and IGF Society, Genoa Italy, Sept 16, 2008.

163. Maile LA, Clemmons DR. Metabolic control of IGF action in vascular cells. Presented to Gordon Research Conference IGFs in physiology and disease. Ventura, Ca, March 21-24, 2009.

164. Shen X, Xi G, Clemmons DR. Recruitment of Pyk2 and PDK1 to SHPS-1 signal complex is required for stimulated Akt activation in vascular smooth muscle cells. Presented to the 91st Annual Meeting of the Endocrine Society, Washington, DC June 10-13, 2009

165. Kawai M, DeMambro VE, Breggia A, Beamer WG, Clemons Dr, Rosen CJ. IGFBP-2 regulates bone turnover through a mechanism that is independent of IGF binding. Presented to the 91st Annual Meeting of the Endocrine Society, Washington, DC June 10- 13, 2009

166. Radhakrishnan Y, Maile LA, Clemmons DR. Insulin receptor substrate 1 impairs SHPS-1 mediated signaling in smooth muscle cells in response to IGF-I. Presented to the 91st Annual Meeting of the Endocrine Society, Washington, DC June 10-13, 2009

167. Xi G, Shen X, Clemmons DR. p66Shc inhibits IGF-I signaling via direct binding of its polyproline the c-Src SH3 domain which inhibits Src kinase activation. Presented to the 91st Annual Meeting of the Endocrine Society, Washington, DC June 10-13, 2009

168. Xi G, Shen X, Clemmons DR. High glucose enhances IGF-I stimulated Src activation viat upregulating Nox4 through a PKCζ dependent mechanism in smooth muscle cells. Presented to the 91st Annual Meeting of the Endocrine Society, Washington, DC June 10- 13, 2009

169. Izawa T, Clemmons DR. Effect of Rho/ROCK pathway on insulin-like growth factor-1 (IGF-1) in smooth muscle cells. Presented to the 91st Annual Meeting of the Endocrine Society, Washington, DC June 10-13, 2009

170. Kawashima Y, Fritton CJ, Elis S, Courtland HW, Sun H, Wu Y, Rosen CJ, Clemmons DR. Reduced IGF-1 complex formation leads to increased marrow. Presented to the 91st Annual Meeting of the Endocrine Society, Washington, DC June 10-13, 2009

51 171. Cascella T, Maile LA, Colao A, Clemmons DR. Aldosterone modulation of IGF-I mediated signal pathway in vascular muscle cells. Presented to the 91st Annual Meeting of the Endocrine Society, Washington, DC June 10-13, 2009

172. Baumann G, Zimmermann AG, Ross R, Clemmons DR, Woodmansee W. Prevalence of diabetes in growth hormone deficient patients receiving growth hormone. Presented to the 91st Annual Meeting of the Endocrine Society, Washington, DC June 10-13, 2009

173. Xi G, Shen X, Clemmons DR. Oxidation of Src by Nox4 derived ROS is required for the enhancement of IGF-I signaling and biological actions in response to hyperglycemia in smooth muscle cells. (SMC). Presented to the 92nd Annual Meeting of the Endocrine Society, San Diego, Ca, June 19-22, 2010.

174. Maile LA, Wai C, Rosen CJ, Clemmons DR. IAP association with SHPS-1 regulates osteoclast fusion. Presented to the 92nd Annual Meeting of the Endocrine Society, San Diego, Ca, June 19-22, 2010.

175. Shen X, Xi G, Radhakrishnan Y, Clemmons DR. Recruitment of PDK1 to the SHPS-1 signaling complex enhances IGF-I stimulated AKT activation in vascular smooth muscle cells (VSMC). Presented to the 92nd Annual Meeting of the Endocrine Society, San Diego, Ca, June 19-22, 2010.

176. Maile LA, Gollahon KG, Allen LB, Wai C, Dunbar P, Clemmons DR. The role of hyperglycemia induced increase in IAP association with SHPS-1 in diabetic retinopathy. Presented to 92nd Annual Meeting of the Endocrine Society, San Diego, Ca, June 19-22, 2010.

177. Xi G, Shen X, Clemmons DR. High glucose induced p66Shc inhibits IGF-I dependent cell survival and protein synthesis via impairment of PI3K/AKT activation in SMC. Presented to 92nd Annual Meeting of the Endocrine Society, San Diego, Ca, June 19-22, 2010.

178. Ning J, Clemmons DR. IGF-I suppresses AMPK activity through stimulation of Akt mediated phosphorylation of AMPk at S485. Presented to 92nd Annual Meeting of the Endocrine Society, San Diego, Ca, June 19-22, 2010.

179. Solum AM, Busby WH, Rosen CJ, Clemmons DR. A unique heparin binding domain of IGFBP-2 is active in inhibiting adipogenesis in an IGF-I independent manner. Presented to 92nd Annual Meeting of the Endocrine Society, San Diego, Ca, June 19-22, 2010.

180. Zhong Y, Zhou J, Li Y, Lu L, Clemmons DR, Duan C. IGF binding protein-3 exerts its IGF-I independent action by antagonizing BMP Action in vivo. Presented to 92nd Annual Meeting of the Endocrine Society, San Diego, Ca, June 19-22, 2010.

181. Breggia AC, Kawai M, Grlickova-Duzevik E, Clemmons DR, Rosen CJ. Global deletion of IGFBP-2 disrupts hematopoiesis and compromises bone marrow engraftment in lethally irradiated mice. Presented to 92nd Annual Meeting of the Endocrine Society, San Diego, Ca, June 19-22, 2010.

182. Maile LA, Wai C, Cascella T, Rosen CJ, Clemmons DR. Regulation of osteoclast differentiation by the IGF binding protein IGFBP-2. Presented to 92nd Annual Meeting of the Endocrine Society, San Diego, Ca, June 19-22, 2010.

52 183. Gollahon K, Allen LB, Wai C, Dunbar P, Clemmons DR, Maile LA. The role of hyperglycemia induced increase in IAP association with SHPS-1 in diabetic retinopathy. Presented to FASEB Summer Research Conference Thrombospondins and other matricellular proteins, Snowmass, Co, July 21-26, 2010.

184. Maile LA, Gollahon K, Allen LB, Wai C, Dunbar P, Hartnett ME, Clemmons DR. A novel approach to inhibit retinal neovascularization. Presented to ARVO Summer Research Conference, Bethesda Md, July 28-30, 2010.

185. Maile LA, Gollahon K, Allen LB, Wai C, Dunbar P, Clemmons DR. A novel approach to inhibit vascular permeability and retinal leukostasis in a rodent model of diabetic retinopathy. Presented to ARVO Summary Research Conference, Bethesda, Md, July 28-30, 2010.

186. Maile LA, Gollahon K, Allen LB, Wai C, Dunbar P, Hartnett ME, Clemmons DR. Inhibiting IGF-I action inhibits the development and progression of diabetic retinopathy in vivo. Presented to Fifth International Congress of the GRS and IGF society, New York, NY, October 13-14, 2010.

187. Dunbar P, Maile LA, Clemmons DR. Identification of the IAP binding site for SHPS-1 and its role in the regulation of IGF-I signaling. Presented to Fifth International Congress of the GRS and IGF society, New York, NY, October 13-14, 2010.

188. Xi G, Shen X, Clemmons DR. Corecruitment of NAPD oxidase NOX4 and Src to the scaffolding protein SHPS-1 results in localized Src oxidation and activation which modifies enhancement of the VSMC proliferation response to IGF-I. Presented to the 93rd Annual Meeting of the Endocrine Society, Boston Ma, June 4, 2010.

189. Breggia A, McMinale M, Kawai M, Clemmons DR and Rosen CJ. The heparin binding domain of IGFBP-2 increases proliferation of human hematopoetic stem cells in vitro. Presented to the 93rd Annual Meeting of the Endocrine Society, Boston Ma, June 4, 2011.

190. Shen X, Xi G, Maile LA, Rosen CJ and Clemmons DR. Determination of the mechanism by wich IGFBP-2 regulates PTEN/AKT signal transduction in vascular smooth muscle cells (VSMC). Presented to the 93rd Annual of the Endocrine Society, June 6, 2011. 191. Maile LA, Gollahan K, Wai C, Clemmons DR. αVβ3 integrin and diabetic nephropathy. Presented to the 53rd Annual Meeting of the American Diabetes Association San Diego, CA June 23, 2011.

192. Maile LA, Gollahan K, Flowers C, Bellinger DA, Nichols T and Clemmons DR. An anti αVβ3 antibody inhibits coronary artery atherosclerosis in diabetic pigs. Presented to the 47th Annual Meeting of the American Heart Association, Orlando Fl, Nov 3, 2011.

INVITED LECTURES (Past six years only)

53 1. Diagnosis and treatment of disorders of growth hormone growth hormone secretion. Presented to Medical Grand Rounds, University of Florida, Gainesville, Florida, January 8, 2004.

2. Mechanisms by which specific integral membrane proteins modulate IGF-I actions. Presented to Endocrine Research Conference, University of Florida, Gainesville Florida, January 8, 2004.

3. Role of IGF-I in regulating glucose homeostasis. Presented to 9th Annual KIM/KIGS Meeting, Paris, France, January 16, 2004.

4. Pathophysiology of growth hormone and IGF-I: Relevance to bone disease. Presented to New England Bone Meeting, Sugarloaf, Maine, January 30, 2004.

5. Molecular mechanisms regulating IGF-I signaling. Presented to Hormone Action Group, Environmental Health Sciences, Research Triangle Park, North Carolina, February 3, 2004.

6. Transitioning pediatric patients with Growth Hormone Deficiency to adult clinics. Presented to 6th HYPOCCS Symposium, San Antonio, Texas, March 13, 2004.

7. Role of IGF-I in regulation insulin resistance. Pleary Lecture Annual Meeting of the Italian Endocrine Society, Genova, Italy, March 26, 2004.

8. Diagnosis and treatment of Acromegaly. Presented to Colorado Endocrine Club, Denver, Colorado, March 30, 2004.

9. Role of IGF-I in enhancing Insulin action. Endocrine Grand Rounds University of Colorado, School of Medicine, March 31, 2004.

10. Mechanisms by which integral membrane proteins regulate IGF-I action. Presented to Endocrine Division, Research Conference. University of Colorado, School of Medicine, Denver Colorado, March 31, 2004.

11. Insulin resistance and atherosclerosis. Presented to the 18th Annual Internal Medicine Conference, UNC School of Medicine, Chapel Hill, North Carolina, April 2, 2004.

12. Insulin resistance in acromegaly. Presented to the 8th International Endocrine Conference on Pituitary Diseases. Sorrento, Italy, April 27, 2004.

13. Molecular mechanisms of IGF-I actions. Symposium on Insulin-like Growth Factors, Karolinskea Institute, Stockholm, Sweden, May 7, 2004.

14. Insulin-like growth factor binding protein proteins. Seminar Dyax, Inc. Cambridge, MA, May 10, 2004.

15. Integral membrane proteins that regulated IGF-I actions. Presented to a Symposium on Insulin-like Growth Factors Geneva Switzerland, May 15, 2004.

16. Vascular disease in acromegaly. Presented to the 25th KIMS/KIGS Symposium, Geneva, Switzerland, May 17, 2004.

54 17. Nichols T Zervas Annual Lectureship. Massacheusttes General Hospital, IGF-I and the mechanism by which it regulates cell growth. Boston, MA, May 20, 2004.

18. IGF-I as a diagnostic test. Serono Symposium on disorders of growth hormone. New Orleans, LA, June 14, 2004.

19. Diagnosis and treatment of pituitary disorders. Endocrine Fellows Foundation, New Orleans, LA, June 15, 2004.

20. Symposium on acromegaly. Presented to the 86th Annual Meeting of the Endocrine Society, New Orleans, LA, June 16, 2004.

21. Symposium on hypopituitarism. Presented to the 86th Annual Meeting of the Endocrine Society, New Orleans, June 18, 2004.

22. Role of IGF-I in vascular diseases. Endocrine Grand Rounds, UCLA Medical Center, Los Angeles, CA, July 1, 2004.

23. Diagnosis and treatment of disorders of growth hormone secretion. American Association of Clinical Endocrinology, Florida Chapter, Ft Lauderdale, Florida, August 6, 2004.

24. Molecular mechanisms of insulin resistance, Endocrine Grand Rounds, Duke University, Durham, NC, August 9, 2004.

25. Growth factor receptor signaling. Twelfth International Congress of Endocrinology, Lisbon Portgual, Sept, 3, 2004.

26. Diagnosis and treatment of adult growth hormone deficiency. American Association Clinical Endocrinology. Savannah, Georgia, Sept 18, 2004.

27. Role of growth hormone in mediating insulin resistance. American Heart Association Regional Meeting, New York, NY, October 1, 2004.

28. Diagnosis and treatment of acromegaly. Boston Endocrine Association, Boston Mass, October 12, 2004.

29. Diagnosis and treatment of disorders of growth hormone secretion. Washington Endocrine Club, Washington, DC. November 9, 2004.

30. Evaluation of pituitary disorders: Endocrine Club Columbus, Ohio, November 16, 2004.

31. Diagnosis and treatment of Acromegaly. Regional Endocrinology Meeting, Carlsbad Ca, January 14, 2005.

32. IGF-I in metabolic bone disease. Conference on Metabolic Bone Disease. Sugarloaf, Maine, January 28, 2005.

33. Chair session on IGF-I and Vascular Diseases. Gordon Research Conference, Ventura California, March 2, 2005.

55 34. Roles of IGF-I measurements in monitoring the response to treatment in Acromegaly. 23rd Annual KIMS/KIGS Meeting, Athens, Greece, March 5, 2005.

35. Diagnosis and treatment of acromegaly. Atlanta Endocrine Club, Atlanta, Ga., April 5, 2005.

36. Physiologic regulation of glucose homeostasis by IGF-I. Endocrine Grand Rounds, Vanderbilt University, Nashville, Tenn, April 12, 2005.

37. Diagnosis and management of subclinical hypothyroidism. UNC Continuing Education Course, April 13, 2005.

38. Diagnosis of pituitary disorders. Medical Grand Rounds, LSU School of Medicine, Shreveport, LA April 19, 2005.

39. Diagnosis and management of disorders of growth hormone secretion. Medical Grand Rounds, New York University, May 11, 2005.

40. IGF-I: Physiologic role and changes in growth hormone in pathophysiologic states. Endocrine Grand Rounds, New York Univ, May 13, 2005.

41. Gerald Aurbach Lecture: Molecular mechanisms of IGF-I actions and their alteration in diabetes. Plenery Lecture Endocrine Society Annual Meeting, San Diego, Ca, June 3, 2005.

42. Plenery Lecture: Role of IGF-I in maintaining normal protein balance. Pituitary Society Annual Meeting, San Diego, CA, June 7, 2005.

43. IGF-I receptor interactions. Presented to MD-PhD program, Wake Forest Univ. Winston- Salem, NC, August 26, 2005.

44. Mechanisms by which GH receptor antagonists regulate GH and IGF-I actions. Presented to Second Annual Meeting European Endocrine Society, Gothenburg Sweden, September 3, 2005.

45. Use of IGF-I as a diagnostic test. Endocrine Grand Rounds, Cleveland Clinic, Cleveland Ohio, Sept 15, 2005.

46. Molecular mechanisms of IGF-I actions. Endocrine Research Conference, Mayo Clinic, Rochester, Minnesota, Sept 28, 2005.

47. Relationship between IGF-I and protein balance. Endocrine Grand Rounds, Mayo Clinic. Sept 29. 2005.

48. IGF-I in the diagnosis and treatment of acromegaly. Endocrine Grand Rounds, Downstate Medical Center. New York, NY. Oct 17, 2005.

49. Role of diabetes in altering bone metabolism. New England Bone Society Meeting. Portland, Maine. October 27, 2005.

50. Alteration in IGF-I actions in diabetes and atherosclerosis. Presented to International Conference on IGF-I receptor function. Toramina Sicily, Nov 11, 2005.

56 51. Disorders of growth hormone. Update in Endocrinology Post Graduate Course, Snowmass Colorado, January 21-23, 2006.

52. Role of IGF-I in diabetes complications. Presented to Roche Pharmaceuticals Basal Switzerland, Jan 25, 2006.

53. Effect of medical therapy on reduction comborbidities. Consensus Conference on Acromegaly, Santa Monica, Ca, February 20-22, 2006.

54. Diagnosis and management of acromegaly. Continuing education course in pituitary disease, Cleveland Clinic, Cleveland, Ohio, March 10, 2006.

55. Development of a model of atherosclerosis in type II diabetic pigs. Presented to AMDCC meeting, Baltimore, Maryland, March 22, 2006.

56. Role of IGF-I receptor in growth regulation. Novartis, Basking Ridge, New Jersey, March 23, 2006.

57. Diagnosis and management of growth hormone deficiency. Post graduate course, Massachusetts General Hospital, Boston Mass, April 1-2, 2006.

58. Role of IGFBP-5 in regulating IGF-I actions. Visiting Professor, NYU School of Medicine, Endocrine Grand Rounds, NYU School of Medicine, New York, NY, May 11-12, 2006.

59. Role of IGF-I in controlling muscle protein synthesis. Norvatis, Cambridge, Mass May 31, 2006.

60. IGF-I and its role in cell growth. Symposium on growth regulation. Endocrine Society Annual Meeting, Boston Mass, June 23, 2006.

61. Role of IGF-I in regulating signaling between nutrient intake and cell growth. American Association of Animal Science, Annual Meeting, Minneapolis, Mn July 11, 2006.

62. Role of IGF-I in controlling insulin action. Visiting Professor, Endocrine Grand Rounds, Cornell University Medical Center, New York, NY Sept 7, 2006.

63. Regulation of IGF-I actions. Visiting Professor, University of Tokyo, Biochemistry Department, Tokyo Japan, Nov 7, 2006.

64. Plenary Lecture: Hyperglycemia sensitizes smooth muscle cells to the proliferative effects of IGF-I. Presented to the 6th International Meeting of the IGF-I Society, Kobe Japan, November 9, 2006.

65. Role of IGF-I in cell cycle regulation. Ibsen Endocrine Symposium in Cell Cycle Regulation. Paris France, December 4, 2006.

66. IGF-I and vascular smooth muscle growth regulation. Presented to the Department of Physiology Science, UNC School of Medicine, Chapel Hill, NC Jan 8, 2007.

67. Hyperglycemia regulates the ability of smooth muscle cells to respond to IGF-I. Presented to the Receptor Research Group, NIEHS, Research Triangle Park, NC, Feb 6, 2007.

68. Use of IGF-I measurements in diagnosing disorders of growth hormone secretion and in monitoring therapy. Medical Grand Rounds, University of Pennsylvania, Feb 27, 2007.

69. Hyperglycemia alters vascular proliferation responses to IGF-I: Mechanisms of growth dysregulation. Endocrine Research Conf., University of Pennsylvania, Feb 28, 2007.

70. IGF-I as a biomarker of growth hormone actions. Presented to workshop on Diagnosis of Growth Hormone Deficiency. Sydney Austrialia, March 13, 2007.

71. Technical pitfalls in measuring IGF-I. Presented Workshop on Diagnosing Growth Hormone Deficiency. Sydney, Australia, March 14, 2007.

72. Molecular mechanisms that regulate the hyperglycemia stress response in vascular smooth muscle. Presented to Gordon Conference on Insulin-like growth factors. Ventura California, March 21, 2007.

73. Visiting Professor, University of Utah. Diagnosis and treatment of disorders of growth hormone secretion. Endocrine Grand Rounds, April 26, 2007.

74. Molecular mechanism by which vascular smooth muscle cells adapt to hyperglycemic stress. Present to Endocrine Research Conference, Univ of Utah, April 27, 2007.

75. Long acting forms of growth hormone and GHRH. Presented to the 29th Annual Meeting of the KIGS KIMS Investigators, Berlin Germany May 9, 2007.

76. The diagnosis of acromegaly and assessment of disease activity. Presented to Symposium Annual Meeting of The Endocrine Society, Toronto, Canada, June 4, 2007.

77. Animal models of vascular complications of diabetes and chronic diseases. Presented to a workshop on Animal Models of Aging. National Institutes on Aging, Bethesda, Maryland, September 10-11, 2007.

78. Mechanisms of modifying the effect of hyperglycemia on vascular responses. Presented to the Juvenile Diabetes Foundation Investigators meeting, New York, New York, October 10-11, 2007.

79. Role of hyperinsulinemia in vascular function. Presented to a symposium on New Approaches to Studying Vascular Complications of Metabolic Disorders. Annual Meeting of the American Heart Association, Orlando Florida, November 4-5, 2007.

80. Monitoring Comobidities in Acromegaly. Presented to a Concensus Conference Meeting, Miami Florida, November 6-7, 2007.

81. Diagnosis and treatment of growth hormone deficiency in Adults. Presented to the Annual Meeting of the Puerto Rico Endocrine Society, San Juan, Puerto Rico, December 4-7, 2007.

82. Hyperglycemia sensitizes vascular smooth muscle cells to the proliferative effects of IGF- I. Presented to Diabetes Research Conference, Mt Sinai School of Medicine, New York, New York January 14, 2008.

58 83. IGF-I and its role in diagnosis and treatment of disorders of growth hormone secretion. Endocrine Grand Rounds. Mt Sinai School of Medicine, New York, New York, January 14, 2008.

84. Molecular Mechanisms by which hyperglycemia accelerates the development of atherosclerosis. Presented to Keystone Meeting on Molecular Mechanisms of Aging. Copper Mountain, Colorado, March 31, 2008

85. Role of obesity in enhancing sensitivity to GH and IGF-I. Presented to 6th HYPOCCS Symposium. Vancover, Canada, April 3, 2008.

86. Mechanisms by which IGF-I regulates muscle protein synthesis. Presented to Banbury Conference on muscle cell biology. April 8, 2008.

87. Interaction between hyperglycemia and IGF-I signaling pathways in atherosclerosis. Endocrine Grand Rounds, University of Virginia, Charlottesville, Va Apri 29,2008.

88. Vascular responses to hyperglycemic stress. Endocrine Grand Rounds, Brigham and Women’s Hospital, Harvard Medical School, Boston Mass, May 14, 2008.

89. IAP cleavage in its role in diabetes complications. Presented to NIEHS, Research Triangle Park, NC May 16, 2008.

90. IAP/SHPS-1 interaction in the regulation of IGF-I sensitivity. Presented to Biochemistry Department UNC School of Medicine, October 7, 2008.

91. Role of αVβ3 in regulating IGF-I sensitivity in atherosclerosis. Endocrine Grand Rounds, University of Virginia, October 16, 2008.

92. IAP/SHPS-1 and their roles in diabetic atherosclerosis. Presented to Endocrine Grand Rounds Maine Medical Center, Portland Main October 30, 2008.

93. IGFBP-2 and its role in the regulation of bone mineral density. Presented to New England Bone Clinic, Portsmouth NH, October 31, 2008.

94. αVβ3 integrin and its role in regulating IGF-I actions in diabetes. Presented to Ibsen Foundation Symposium on IGFs and Growth Factors. Paris France, November 30, 2008.

95. Comorbidities in Acromegaly. Presented to the 10th International Consensus Conference on Acromegaly. Paris France, April 2, 2009.

96. Role of IGF-I Receptor in Cancer. Presented to the European Oncology Society Research Forum, Munich Germany, April 13, 2009.

97. IAP/SHPS-1 association and its importance in regulating IGF-I actions in diabetes. Presented to the Receptor physiology and signaling seminar, NIEHS, Research Triangle Park, NC, May 5, 2009.

98. Management of complications of Acromegaly. Presented to Symposium on Acromegaly at the 81st Annual Meeting of the Endocrine Society, Washington, DC, June 10, 2009.

59 99. IGF-I measurements in diagnosis and management. Presented to Consensus Workshop on GH and IGF-I assays. Growth Hormone and IGF-I Research Society. Kenwick, VA, October 14, 2009.

100. Growth hormone replacement therapy and the development of hyperglycemia. Presented to Eli Lilly Inc, Indianopolis, Inc, March 21, 2010.

101. Translational research. Presented to a Symposium of European Society of Pediatric Endocrinology, Varberg Sweden, May 20, 2010.

102. Role of hyperglycemia in regulating the responses of vascular cells to IGF-I. Presented to a Symptom of the European Society of Pediatric Endocrinology, Varberg, Sweden, May 22, 2010.

103. Growth hormone insulin sensitivity. Presented to a symposium on growth hormone replacement therapy. 92nd Annual Meeting of the Endocrine Society, San Diego, Ca, June 20, 2010.

104. Role of thrombospondin in regulating IGF-I actions in the vasculature. Presented to FASEB conference on thrombospondin. Snowmass, Co, July 19, 2010.

105. Development of hyperglycemia in growth hormone deficient patients being treated with growth hormone. Presented to European Endocrine Conference on Growth Hormone Deficiency. Vienna Australia, November 20, 2010.

106. Role of IGF-I in regulating the response of vascular cells to hyperglycemic stress. Medical Grand Rounds, Main Medical Center Research Institute. Scarborough Maine, February 3, 2011.

107. IGF-I regulation of glucose metabolism in diabetes. Presented to International Symposium on IGF-I GH and Ghrelin, Orlando Florida, March 6, 2011.

108. IGF-I and acromegalic comorbidities. Presented to 9th Symposium on New treatments for Acromegaly. London UK, March 22, 2011.

109. Role of IGFBP-2 in modulating IGF-I actions. Presented to Receptor Activation Group, National Institutes for Environmental Health Sciences, Res Triangle Park, NC, May 3, 2011.

110. Introduction to Endocrinology. Presented to the 48th Annual European Endocrine Society, Rome Italy, May 20, 2011.

111. Role of IGF-I in the diagnosis and management of disorders of growth hormone secretion. Presented to the 15th Meeting of The Pituitary Society, Boston, MA, June 3, 2011. 112. Role of growth hormone and IGF-I in fat metabolism and the metabolic syndrome. Presented to Symposium on Growth Hormone and IGF-I and Fat Metabolism in the 93rd Annual Meeting of the Endocrine Society, Boston, MA, June 6, 2011.

113. Role of IGFBP-5 and IGF-I in cartilage regeneration. Presented to Symposium on IGF-I in the treatment of Arthritis. Milford MA, June 16, 2011.

60 114. Management of patients with growth hormone deficiency. Presented to the Clinical Endocrine Update by the Endocrine Society, Nashville, Tenn, September 8, 2011.

115. Case Management Discussions. Presented to the Clinical Endocrine Update by the Endocrine Society, Nashville, Tenn, September 8, 2011.

116. Diagnosis monitoring therapy and indications for surgery or radiation therapy in Acromegaly. CME symposium. Sponsored by the Endocrine Society, Nashville, Tenn September 9, 2011.